Hologic (HOLX) 10-Q 3 May 24 2024 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Mar. 30, 2024	Apr. 25, 2024
Cover [Abstract]
Title of 12(b) Security	Common Stock, $0.01 par value
Document Transition Report	false
Document Quarterly Report	true
Entity Incorporation, State or Country Code	DE
Entity Address, Postal Zip Code	01752
Entity File Number	1-36214
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Registrant Name	HOLOGIC, INC
Entity Central Index Key	0000859737
Current Fiscal Year End Date	--09-28
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		233,376,948
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
City Area Code	(508)
Local Phone Number	263-2900
Entity Tax Identification Number	04-2902449
Entity Address, Address Line One	250 Campus Drive,
Entity Address, City or Town	Marlborough,
Entity Address, State or Province	MA
Trading Symbol	HOLX
Security Exchange Name	NASDAQ

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Revenues:
Product	$ 828	$ 837.4	$ 1,656	$ 1,723.8
Service and other	189.8	189.1	374.9	376.9
Revenues	1,017.8	1,026.5	2,030.9	2,100.7
Costs of revenues:
Product	308.6	292.1	615.7	588.3
Amortization, Cost of Goods Sold	44.9	52.1	90.5	107.7
Impairment of intangible asset	25.9	0	25.9	0
Service and other	96.1	96.5	189	201
Gross profit	542.3	585.8	1,109.8	1,203.7
Operating expenses:
Research and development	74.6	74	141.4	148.8
Selling and marketing	144.2	142.4	293.1	305.9
General and administrative	100.4	100.8	212.2	209.3
Amortization of acquired intangible assets	5.7	7.1	19	14.7
Impairment of intangible assets	0.9	0	5.2	0
Contingent consideration - fair value adjustments	0	(12.4)	1.7	(12.4)
Restructuring charges	6.1	1.8	28.6	2.9
Operating expenses	331.9	313.7	701.2	669.2
Income from operations	210.4	272.1	408.6	534.5
Interest income	24	31.5	51.9	52.1
Interest expense	(32.3)	(27.2)	(58.3)	(55.3)
Other income (expense), net	9.4	2.9	0.6	(12.9)
Income before income taxes	211.5	279.3	402.8	518.4
Provision (benefit) for income taxes	41.6	60.8	(13.6)	112.5
Net income	$ 169.9	$ 218.5	$ 416.4	$ 405.9
Net income per common share:
Basic (in usd per share)	$ 0.72	$ 0.88	$ 1.76	$ 1.64
Diluted (in usd per share)	$ 0.72	$ 0.87	$ 1.74	$ 1.63
Weighted average number of shares outstanding:
Basic (in shares)	235,890	247,730	237,258	247,524
Diluted (in shares)	237,562	249,793	238,888	249,537

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Statement of Comprehensive Income [Abstract]
Net income	$ 169.9	$ 218.5	$ 416.4	$ 405.9
Changes in foreign currency translation adjustment	(22.8)	15.3	20.2	129.1
Gain (loss) recognized in other comprehensive income (loss), net	4.6	(6.4)	(9.6)	(9.3)
Other comprehensive income (loss)	(18.2)	8.9	10.6	119.8
Comprehensive income	$ 151.7	$ 227.4	$ 427	$ 525.7

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Statement of Comprehensive Income [Abstract]
Tax	$ 1.4	$ (2)	$ (3)	$ (2.9)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 30, 2024	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 2,180	$ 2,722.5
Accounts receivable, less reserves	647.1	625.6
Inventory	649.2	617.6
Prepaid Expense, Current	165.5	175.3
Prepaid Income Taxes-Current	146.9	31.6
Disposal Group, Including Discontinued Operation, Assets	0	11.9
Total current assets	3,788.7	4,184.5
Property, plant and equipment, net	524.8	517
Intangible assets, net	751.9	888.6
Goodwill	3,292.4	3,281.3
Other assets	356.6	267.9
Total assets	8,714.4	9,139.3
Current liabilities:
Current portion of long-term debt	37.4	287
Accounts payable	202.5	175.2
Accrued expenses	503.5	534.6
Deferred revenue	208	199.2
Finance lease obligations	3.2	3.1
Disposal Group, Including Discontinued Operation, Liabilities, Current	0	8.2
Total current liabilities	954.6	1,207.3
Long-term debt, net of current portion	2,514.1	2,531.2
Finance lease obligations, net of current portion	13.8	15.3
Deferred Income Tax Liabilities, Net	18.4	20.2
Deferred revenue, net of current portion	14.8	13.8
Other long-term liabilities	354.3	334.6
Stockholders’ equity:
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued	0	0
Common stock, $0.01 par value – 750,000 shares authorized; 300,756 and 299,940 shares issued, respectively	3	3
Additional paid-in-capital	6,197.6	6,141.2
Retained earnings	2,472.7	2,056.3
Treasury stock, at cost – 67,380 and 58,231 shares, respectively	(3,691.9)	(3,036)
Accumulated other comprehensive loss	(137)	(147.6)
Total stockholders’ equity	4,844.4	5,016.9
Total liabilities and stockholders’ equity	$ 8,714.4	$ 9,139.3

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Mar. 30, 2024	Sep. 30, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	1,623,000	1,623,000
Preferred stock, issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	750,000,000	750,000,000
Common stock, issued (in shares)	300,756,000	299,940,000
Treasury stock (in shares)	67,380,000	58,231,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Millions	Total	Accelerated Share Repurchase Agreement	Common Stock	Additional Paid-in Capital	Additional Paid-in Capital Accelerated Share Repurchase Agreement	Retained Earnings	Total	Treasury Stock	Treasury Stock Accelerated Share Repurchase Agreement
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 4,876.2
Balance (in shares) at Sep. 24, 2022			298,533					51,401
Beginning balance at Sep. 24, 2022			$ 3	$ 6,042.6		$ 1,600.3	$ (238.2)	$ (2,531.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)			267
Exercise of stock options				10.3
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)			514
Vesting of restricted stock units, net of shares withheld for employee taxes	(23)			(23)
Common stock issued under the employee stock purchase plan (in shares)			171
Common stock issued under the employee stock purchase plan				10.2
Stock-based compensation expense				20.5
Net income	187.4
Other comprehensive income activity							110.9
Repurchase of common stock (in shares)								1,539
Repurchase of common stock								$ (100)
Net income	187.4
Balance (in shares) at Dec. 31, 2022			299,485					52,940
Ending balance at Dec. 31, 2022			$ 3	6,060.6		1,787.7	(127.3)	$ (2,631.5)
Balance (in shares) at Sep. 24, 2022			298,533					51,401
Beginning balance at Sep. 24, 2022			$ 3	6,042.6		1,600.3	(238.2)	$ (2,531.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	405.9
Balance (in shares) at Apr. 01, 2023			299,676					53,566
Ending balance at Apr. 01, 2023			$ 3	6,091.5		2,006.2	(118.4)	$ (2,681.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	5,092.5
Balance (in shares) at Dec. 31, 2022			299,485					52,940
Beginning balance at Dec. 31, 2022			$ 3	6,060.6		1,787.7	(127.3)	$ (2,631.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)			173
Exercise of stock options				7.9
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)			18
Vesting of restricted stock units, net of shares withheld for employee taxes	(0.2)			(0.2)
Stock-based compensation expense				23.2
Net income	218.5
Other comprehensive income activity							8.9
Repurchase of common stock (in shares)								626
Repurchase of common stock								$ (50)
Net income	218.5
Balance (in shares) at Apr. 01, 2023			299,676					53,566
Ending balance at Apr. 01, 2023			$ 3	6,091.5		2,006.2	(118.4)	$ (2,681.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	5,300.8
Exercise of stock options (in shares)			64
Exercise of stock options				3.3
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)			15
Vesting of restricted stock units, net of shares withheld for employee taxes	(0.5)			(0.5)
Common stock issued under the employee stock purchase plan (in shares)			177
Common stock issued under the employee stock purchase plan				11.3
Stock-based compensation expense				16.9
Net income	(40.5)
Other comprehensive income activity							4.8
Repurchase of common stock (in shares)								1,424
Repurchase of common stock								$ (114.1)
Net income	(40.5)
Balance (in shares) at Jul. 01, 2023			299,932					54,990
Ending balance at Jul. 01, 2023			$ 3	6,122.5		1,965.7	(113.6)	$ (2,795.6)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	5,182
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)			8
Vesting of restricted stock units, net of shares withheld for employee taxes	(0.3)			(0.3)
Stock-based compensation expense				19
Net income	90.6
Other comprehensive income activity							(34)
Repurchase of common stock (in shares)								3,241
Repurchase of common stock								$ (240.4)
Net income	90.6
Balance (in shares) at Sep. 30, 2023			299,940					58,231
Ending balance at Sep. 30, 2023	5,016.9		$ 3	6,141.2		2,056.3	(147.6)	$ (3,036)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	5,016.9
Exercise of stock options (in shares)			124
Exercise of stock options				5
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)			432
Vesting of restricted stock units, net of shares withheld for employee taxes				(16.2)
Stock-based compensation expense	28.7			28.7
Net income	246.5
Other comprehensive income activity							28.8
Repurchase of common stock (in shares)								2,161	5,560
Repurchase of common stock		$ (500)			$ (100)			$ (155.9)	$ (400)
Net income	246.5
Balance (in shares) at Dec. 30, 2023			300,496					65,952
Ending balance at Dec. 30, 2023			$ 3	6,058.7		2,302.8	(118.8)	$ (3,591.9)
Balance (in shares) at Sep. 30, 2023			299,940					58,231
Beginning balance at Sep. 30, 2023	5,016.9		$ 3	6,141.2		2,056.3	(147.6)	$ (3,036)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	416.4
Balance (in shares) at Mar. 30, 2024			300,756					67,380
Ending balance at Mar. 30, 2024	4,844.4		$ 3	6,197.6		2,472.7	(137)	$ (3,691.9)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	4,653.8
Balance (in shares) at Dec. 30, 2023			300,496					65,952
Beginning balance at Dec. 30, 2023			$ 3	6,058.7		2,302.8	(118.8)	$ (3,591.9)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)			79
Exercise of stock options				3.2
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)			16
Vesting of restricted stock units, net of shares withheld for employee taxes				(0.1)
Common stock issued under the employee stock purchase plan (in shares)			165
Common stock issued under the employee stock purchase plan				10
Stock-based compensation expense	25.8			25.8
Net income	169.9
Other comprehensive income activity							(18.2)
Repurchase of common stock (in shares)									1,428
Repurchase of common stock		$ 0			$ 100				$ (100)
Net income	169.9
Balance (in shares) at Mar. 30, 2024			300,756					67,380
Ending balance at Mar. 30, 2024	4,844.4		$ 3	$ 6,197.6		$ 2,472.7	$ (137)	$ (3,691.9)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 4,844.4

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions		6 Months Ended
		Mar. 30, 2024	Apr. 01, 2023
OPERATING ACTIVITIES
Net income		$ 416.4	$ 405.9
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		52.6	44.3
Amortization of acquired intangible assets		109.5	122.4
Stock-based compensation expense		54.5	43.7
Deferred income taxes		(46.8)	(61.6)
Intangible asset impairment charges		31.1	0
Change in contingent consideration		1.7	(12.4)
Other adjustments and non-cash items		23	29.6
Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions:
Accounts receivable		(20.1)	(81.8)
Inventories		(30.4)	(56.1)
Prepaid income taxes		(115.3)	8.3
Prepaid expenses and other assets		(12.5)	10.5
Accounts payable		26.7	(13.2)
Accrued expenses and other liabilities		13.3	(22.4)
Deferred revenue		8.7	42.5
Net cash provided by operating activities		512.4	459.7
INVESTING ACTIVITIES
Sale of business, net of cash disposed		(31.3)	0
Capital expenditures		(35.5)	(34.5)
Proceeds received from government grants for capacity expansion		0	20.5
Increase in equipment under customer usage agreements		(30.5)	(26.7)
Payments to Acquire Other Investments		39.5	10
Payments for (Proceeds from) Other Investing Activities		(5.9)	(6.7)
Net cash used in investing activities		(142.7)	(57.4)
FINANCING ACTIVITIES
Repayment of long-term debt		(268.8)	(7.5)
Payment for Contingent Consideration Liability, Financing Activities		(2.6)	(7.6)
Payment of deferred acquisition consideration		0	(0.8)
Repurchase of common stock		(676.8)	(150)
Proceeds from issuance of common stock pursuant to employee stock plans		18.4	28.4
Payment of minimum tax withholdings on net share settlements of equity awards		(16.3)	(23.2)
Payments under finance lease obligations		(1.9)	(2.3)
Net cash used in financing activities		(948)	(163)
Effect of exchange rate changes on cash and cash equivalents		2.6	3.4
Net (decrease) increase in cash and cash equivalents		(575.7)	242.7
Cash and cash equivalents, beginning of period*	[1]	2,755.7	2,339.5
Cash and cash equivalents, end of period		$ 2,180	$ 2,582.2
[1]Includes $33.2 million of cash recorded in assets held-for-sale - current assets as of September 30, 2023.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2023	Sep. 28, 2023
Disposed of by Sale | SSI Ultrasound Imaging Business
Disposal Group, Including Discontinued Operation, Cash	$ 33.2	$ 33.2

Basis of Presentation

Basis of Presentation	6 Months Ended
	Mar. 30, 2024
Basis of Presentation [Abstract]
Basis of Presentation	Basis of Presentation The unaudited consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”) for annual financial statements. These unaudited financial statements should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended September 30, 2023 included in the Company’s annual report on Form 10-K filed with the SEC on November 21, 2023. In the opinion of management, the unaudited financial statements and notes contain all adjustments (consisting of normal recurring accruals and all other necessary adjustments) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented. The unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three and six months ended March 30, 2024 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 28, 2024. Fiscal 2023 was a 53-week fiscal year, and the additional week was included in the first quarter of fiscal 2023 consistent with the Company’s historical fiscal calendar. Subsequent Events Consideration The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events, except as described below, affecting the unaudited consolidated financial statements as of and for the three and six months ended March 30, 2024. On April 26, 2024, the Company executed an agreement to acquire Endomagnetics Ltd (“Endomag”) for a purchase price of approximately $310.0 million, subject to working capital and other customary adjustments. The closing is subject to certain regulatory approvals. Endomag, located in the UK, develops and sells breast surgery localization and lymphatic tracing technologies.

Leases

Leases	6 Months Ended
	Mar. 30, 2024
Leases [Abstract]
Leases	Leases Lessor Activity - Leases where Hologic is the Lessor
Leases	Leases Lessor Activity - Leases where Hologic is the Lessor

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Mar. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Fair Value Measurements Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis The Company has investments in money market funds, United States Treasury bills and commercial paper that are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents on the Consolidated Balance Sheets. The Company also has investments in derivative instruments comprised of interest rate swaps and forward foreign currency contracts, which are valued using analyses obtained from independent third-party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of these derivative contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 11 for further discussion and information on derivative contracts. In addition, the Company has a contingent consideration liability that is recorded at fair value, which is based on Level 3 inputs. The following table summarizes certain fair value information at March 30, 2024 and September 30, 2023 for investment assets and other liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain investments. Fair Value at Reporting Date Using Fair Value Quoted Prices in Significant Significant March 30, 2024 Assets: Money market mutual funds $ 410.2 $ 410.2 $ — $ — U.S. Treasury bills 348.1 348.1 — — Commercial paper 49.8 49.8 — — Interest rate swaps 14.2 — 14.2 — Forward foreign currency contracts 2.9 — 2.9 — Total $ 825.2 $ 808.1 $ 17.1 $ — Liabilities: Contingent consideration $ 1.1 $ — $ — $ 1.1 Forward foreign currency contracts 0.2 — 0.2 — Total $ 1.3 $ — $ 0.2 $ 1.1 September 30, 2023 Assets: Interest rate swaps $ 26.9 $ — $ 26.9 $ — Forward foreign currency contracts 8.4 — 8.4 — Total $ 35.3 $ — $ 35.3 $ — Liabilities: Contingent consideration $ 2.0 $ — $ — $ 2.0 Total $ 2.0 $ — $ — $ 2.0 Liabilities Measured and Recorded at Fair Value on a Recurring Basis Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the three and six month periods ended March 30, 2024 and April 1, 2023 were as follows: Three Months Ended Six Months Ended March 30, 2024 April 1, 2023 March 30, 2024 April 1, 2023 Balance at beginning of period $ 3.7 $ 23.4 $ 2.0 $ 23.4 Contingent consideration recorded at acquisition — — — — Fair value adjustments — (12.4) 1.7 (12.4) Payments (2.6) (7.6) (2.6) (7.6) Balance at end of period $ 1.1 $ 3.4 $ 1.1 $ 3.4 Assets Measured and Recorded at Fair Value on a Nonrecurring Basis The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of equity investments and long-lived assets, including property, plant and equipment, intangible assets and goodwill. During the second quarter of fiscal 2024, the Company recorded intangible asset impairment charges of $25.9 million and $0.9 million, respectively, related to its BioZorb developed technology and trade name intangible assets acquired in the Focal acquisition, which is within the Breast Health reportable segment (see Note 18 for further discussion), reducing the carrying value of the assets to $13.9 million and $0.5 million, respectively. During the first quarter of fiscal 2024, the Company recorded a $12.5 million impairment charge for right of use lease assets related to the planned closure of its Mobidiag facilities in Finland and France (see Note 8 for further discussion), reducing the carrying value to zero. In addition, during the first quarter of fiscal 2024, the Company recorded a $4.3 million impairment charge for an in-process research and development project from the Mobidiag acquisition, reducing the carrying value of this asset to $22.4 million. There were no other remeasurements in the three and six months ended March 30, 2024 and April 1, 2023. Disclosure of Fair Value of Financial Instruments The Company’s financial instruments mainly consist of cash and cash equivalents, United States Treasury bills, commercial paper, accounts receivable, equity investments, interest rate swaps, forward foreign currency contracts, insurance contracts, accounts payable and debt obligations. The carrying amounts of the Company’s cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s United States Treasury bills, commercial paper, interest rate swaps and forward foreign currency contracts are recorded at fair value. The carrying amount of the insurance contracts are recorded at the cash surrender value, as required by U.S. GAAP, which approximates fair value. The Company believes the carrying amounts of its equity investments approximate fair value. The Company’s cash and cash equivalents, including current marketable securities, as of March 30, 2024 are as follows: Valuation Balance Sheet Classification in millions Cost Unrealized Gains Unrealized Losses Fair Value Cash and cash equivalents Investments Cash $ 1,371.9 $ — $ — $ 1,371.9 $ 1,371.9 $ — Money market mutual funds 410.2 — — 410.2 410.2 — U.S. Treasury bills 348.0 0.1 — 348.1 348.1 — Commercial paper 49.8 — — 49.8 49.8 — Total $ 2,179.9 $ 0.1 $ — $ 2,180.0 $ 2,180.0 $ — The Company classifies its debt securities as available-for-sale and records them at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss), which was immaterial for the period ended March 30, 2024. The Company periodically assesses these securities for potential impairment losses and credit losses. The amount of credit losses, if any, will be determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. There were no impairments and credit losses related to available-for-sale securities for the three and six months ended March 30, 2024. The Company classifies all highly liquid investments with stated maturities of three months or less from the date of purchase as cash equivalents. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the three and six months ended March 30, 2024 and April 1, 2023, respectively. There were no sales of available-for-sale securities during the three and six months ended March 30, 2024. The March 30, 2024 balance of available-for-sale debt securities by contractual maturity is shown in the following table. The fair value of the available-for-sale securities by maturity as of March 30, 2024 and September 30, 2023 are as follows: March 30, 2024 September 30, 2023 in millions Fair Value Fair Value Due in three months or less $ 397.9 $ — Total available-for-sale securities $ 397.9 $ — Amounts outstanding under the Company’s 2021 Credit Agreement of $1.2 billion aggregate principal as of March 30, 2024 are subject to variable rates of interest based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company’s 4.625% Senior Notes due 2028 (the “2028 Senior Notes”) and 3.250% Senior Notes due 2029 (the “2029 Senior Notes”) had fair values of $385.9 million and $852.6 million, respectively, as of March 30, 2024 based on their trading prices, representing a Level 1 measurement.

Business Combinations

Business Combinations	6 Months Ended
	Mar. 30, 2024
Business Combinations [Abstract]
Business Combinations	Business Combinations Fiscal 2023 Acquisitions JW Medical On July 3, 2023, the Company completed the acquisition of assets from JW Medical Corporation (“JW Medical”) for a purchase price of $6.7 million. JW Medical was a long-standing distributor of the Company’s Breast Health products in South Korea. The majority of the purchase price was allocated to a customer relationship intangible asset with a useful life of 5 years. Normedi On April 3, 2023, the Company completed the acquisition of Normedi Nordic AS (“Normedi”) for a purchase price of $7.7 million. Normedi was a long-standing distributor of the Company’s Surgical products in the Nordics region of Europe. The purchase price included $1.1 million for contingent consideration based on incremental revenue growth over a 2-year measurement period. The Company allocated $3.0 million of the purchase price to a customer relationships intangible asset with a useful life of 5 years, and the excess of the purchase price over the net assets acquired was recorded to goodwill. Contingent Consideration The Company’s primary contingent consideration liability was related to its acquisition of Acessa Health, Inc. (“Acessa”), which was acquired in August 2020. Acessa developed the ProVu laparoscopic radiofrequency ablation system. The Company estimated the fair value of this liability to be $81.8 million as of the acquisition date. The contingent payments were based on a multiple of annual incremental revenue growth over a three-year period ending annually in December of each of 2021, 2022, and 2023. There was no maximum earnout. Pursuant to ASC 805, Business Combinations (ASC 805), the Company recorded its estimate of the fair value of the contingent consideration liability utilizing the Monte Carlo simulation based on future revenue projections of Acessa, revenue growth rates of comparable companies, implied volatility and applying a risk adjusted discount rate. Each quarter the Company was required to remeasure the fair value of the liability as assumptions change, and such adjustments were recorded in operating expenses. This fair value measurement was based on significant inputs not observable in the market and thus represented a Level 3 measurement as defined in ASC 820, Fair Value Measurements . This fair value measurement was directly impacted by the Company’s estimate of future incremental revenue growth of the business. Accordingly, if actual revenue growth were higher or lower than the estimates within the fair value measurement, the Company would record additional charges or gains. During the second quarter of fiscal 2023, the Company updated its forecasted revenue and recorded a gain of $12.4 million to record the liability at its fair value. The reduction in fair value was due to a decrease in forecasted revenues over the remaining measurement period at that time. During the three months ended December 30, 2023, the third and final measurement period was completed, and the Company recorded a loss of $1.7 million to increase the contingent consideration liability to fair value based on actual revenue results in the final earn-out period. The Company made a final payment of $2.6 million during the second quarter of fiscal 2024.

Strategic Investment

Strategic Investment	6 Months Ended
	Mar. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
Strategic Investment	Strategic Investment Maverix Medical On November 13, 2023, the Company entered into an agreement with KKR Comet, LLC, an affiliate of KKR & Co. Inc. (“KKR Comet”), to form a legal entity to develop and acquire innovative technologies and commercial operations within the lung cancer space. The new entity, named Maverix Medical LLC (“Maverix”), is managed by Ajax Health. As part of this strategic investment, the Company contributed $24.5 million in return for 45% ownership in the Class A Common units of Maverix, and both the Company and KKR Comet have committed to make additional capital contributions in proportion to the ownership percentages upon meeting certain objectives and as approved by the Maverix board. In accordance with ASC 810, Consolidation, and ASC 323, Investments - Equity Method and Joint Ventures, the Company determined that this investment should be accounted for under the equity method, which requires the Company to record its proportional share of the entity’s net income (loss). This investment is recorded within Other assets in the Consolidated Balance Sheets, and the Company’s proportionate share of Maverix’s net loss for the three and six months ended March 30, 2024 was immaterial.

Disposition

Disposition	6 Months Ended
	Mar. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Disposition	Disposition Sale of SuperSonic Imagine Ultrasound Imaging Business On September 29, 2023, the Company executed an agreement to sell its SSI ultrasound imaging business to SSH Holdings Limited for a sales price of $1.9 million in cash. Under the terms of the contract, the Company agreed to fund the SSI business with $33.2 million of cash. The sale was completed on October 3, 2023. The Company also agreed to provide certain transition services for up to one year, depending on the nature of the service. The SSI ultrasound imaging asset group met the criteria to be classified as assets held-for-sale in the fourth quarter of fiscal 2023. As a result, the Company recorded a charge of $51.7 million in the fourth quarter of fiscal 2023 to record the asset group to its fair value less costs to sell pursuant to ASC 360, Property, Plant and Equipment-Impairment or Disposal of Long-Lived Assets . The assets and liabilities of the disposed business at the date of disposition were as follows: Assets: Cash $ 33.2 Accounts receivable 4.5 Inventory 16.2 Prepaid expenses and other assets 8.6 Valuation allowance (50.6) Total assets disposed of $ 11.9 Liabilities: Accounts payable $ 3.1 Accrued expenses 5.1 Total liabilities disposed of $ 8.2 The valuation allowance of $50.6 million was recorded to appropriately reflect the assets held-for-sale classification in the Consolidated Balance Sheet in the fourth quarter of fiscal 2023 relative to the loss recorded and the net tangible assets disposed. The Company concluded that this disposal did not qualify as a discontinued operation as the sale of the SSI ultrasound imaging business was deemed to not be a strategic shift having or that will have a major effect on the Company’s operations and financial results.

Trade Receivables and Allowance

Trade Receivables and Allowance for Credit Losses	6 Months Ended
	Mar. 30, 2024
Receivables [Abstract]
Trade Receivables and Allowance for Credit Losses	Trade Receivables and Allowance for Credit Losses The Company applies ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) to its trade receivables and allowances for credit losses, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity, such as the ongoing and possible future effects of global challenges including macroeconomic uncertainties, such as inflation, rising interest rates and availability of capital markets, and other economic disruptions. To date, the Company has not experienced significant customer payment defaults, or identified other significant collectability concerns. In connection with assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those assets from the portfolios of trade receivables evaluated on a collective basis. The following is a rollforward of the allowance for credit losses as of March 30, 2024 compared to April 1, 2023: Balance at Credit Loss Write-offs, Balance at Six Months Ended March 30, 2024 $ 38.5 $ 5.5 $ (1.3) $ 42.7 April 1, 2023 $ 37.7 $ 1.9 $ (0.2) $ 39.4

Restructuring

Restructuring	6 Months Ended
	Mar. 30, 2024
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure	(8) Restructuring During the first quarter of fiscal 2024, the Company further refined its strategy for the Mobidiag business, which is within the Diagnostics reportable segment. The strategy change included the decision to discontinue the manufacture and sale of certain products, closure of its facilities in Finland and France, and to move the development activities and operations to the Company’s San Diego, California location. As such, the Company determined certain fixed assets lives should be shortened and that lease assets were impaired at the affected facilities and recorded accelerated depreciation of $7.2 million and a lease asset impairment charge of $12.5 million. In connection with this plan, the Company finalized its decision to terminate the employees at these locations, totaling 190. The Company initiated discussions with the respective Works Councils at the end of the first quarter of fiscal 2024. In addition, the Company recorded the minimum statutory severance benefit for the employees located in France of $1.8 million pursuant to ASC 712, Compensation Nonretirement Postemployment Benefits . During the second quarter of fiscal 2024, the Company finalized its negotiations with the respective Works Councils and communicated the termination and related severance benefits to the affected employees. The Company has estimated the total severance charges, including accelerated stock compensation, to be approximately $12.2 million. The majority of the severance benefits will be recorded pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420), which requires the severance benefits to be recognized ratably over the service period to obtain such benefits. The employees will cease employment in phases. During the second quarter of fiscal 2024, the Company recorded $4.0 million for severance benefits. This action is expected to be completed by the second quarter of fiscal 2025. During the first quarter of fiscal 2022, the Company finalized its decision to close its Danbury, Connecticut facility where it manufactures its Breast Health capital equipment products. The manufacturing of the Breast Health capital equipment products and all other support services are in the process of being transferred to the Company’s Newark, Delaware facility. The transition is expected to be completed by the third quarter of fiscal 2025. In addition, research and development, sales and services support and administrative functions have been transferred to the Newark, Delaware and Marlborough, Massachusetts facilities. The employees were notified of the closure during the first quarter of fiscal 2022, and the majority of employees located in Danbury were given the option to relocate to the new locations. The Company is recording severance benefits ratably over the required service period pursuant to ASC 420. As a result, the Company recorded severance and benefits charges of $1.3 million and $1.8 million during the three and six months ended March 30, 2024, respectively, and $0.3 million and $1.0 million during the three and six months ended April 1, 2023, respectively. The Company estimates that total severance charges, including retention, will be approximately $7.5 million.

Borrowings and Credit Arrangeme

Borrowings and Credit Arrangements	6 Months Ended
	Mar. 30, 2024
Debt Disclosure [Abstract]
Borrowings and Credit Arrangements	Borrowings and Credit Arrangements The Company’s borrowings consisted of the following: March 30, September 30, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ 37.4 $ 287.0 Total current debt obligations $ 37.4 $ 287.0 Long-term debt obligations, net of debt discount and issuance costs: Term Loan $ 1,177.1 $ 1,195.6 2028 Senior Notes 397.2 396.8 2029 Senior Notes 939.8 938.8 Total long-term debt obligations $ 2,514.1 $ 2,531.2 Total debt obligations $ 2,551.5 $ 2,818.2 2021 Credit Agreement On September 27, 2021, the Company refinanced its then existing term loan and revolving credit facility with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders (the “2018 Credit Agreement”) by entering into a Refinancing Amendment (the “2021 Credit Agreement”). On August 22, 2022, the Company further amended the 2021 Credit Agreement to address the planned phase out of LIBOR by the UK Financial Conduct Authority. Under this amendment, the interest rates applicable to the loans under the 2021 Credit Agreement denominated in U.S. dollars were converted to a variant of the secured overnight financing rate (“SOFR”), as established from time to time by the Federal Reserve Bank of New York, plus a corresponding spread. The 2021 Credit Agreement provided a $1.5 billion secured term loan facility (the “2021 Term Loan”) and a $2.0 billion revolving credit facility (the “2021 Revolver”). As of March 30, 2024, the principal amount outstanding under the 2021 Term Loan was $1.2 billion, and the interest rate was 6.43% per annum. No amounts were outstanding under the 2021 Revolver, and the full amount was available to be borrowed by the Company. During the first quarter of fiscal 2024, the Company made a $250.0 million voluntary prepayment on the 2021 Term Loan. Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2021 Credit Agreement were as follows: Three Months Ended Six Months Ended March 30, 2024 April 1, 2023 March 30, 2024 April 1, 2023 Interest expense $ 21.2 $ 22.5 $ 43.8 $ 42.9 Weighted average interest rate 6.43 % 5.74 % 6.43 % 5.39 % Interest rate at end of period 6.43 % 5.91 % 6.43 % 5.91 % The Company’s effective interest rate swap agreements, the first of which fixed the SOFR component of the variable interest rate on $1.0 billion of aggregate principal under the 2021 Term Loan at 1.23% and terminated on December 17, 2023, and the second of which fixes the SOFR component of the variable interest rate on $500 million of aggregate principal under the 2021 Term Loan at 3.46% commencing on December 17, 2023 and terminating on December 27, 2024, resulted in the Company receiving $2.4 million and $12.0 million during the three and six months ended March 30, 2024, respectively, and $8.6 million and $15.2 million during the three and six months ended April 1, 2023, respectively. These amounts were recorded as a reduction to interest expense. The 2021 Credit Agreement contains two financial covenants; a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2021 Credit Agreement. As of March 30, 2024, the Company was in compliance with these covenants. 2028 Senior Notes As of March 30, 2024, the Company had 4.625% Senior Notes due 2028 (the “2028 Senior Notes”) outstanding in the aggregate principal balance of $400 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company’s domestic subsidiaries and mature on February 1, 2028. 2029 Senior Notes As of March 30, 2024, the Company had 3.250% Senior Notes due 2029 (the “2029 Senior Notes”) outstanding in the aggregate principal balance of $950 million. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company’s domestic subsidiaries and mature on February 15, 2029. Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows: Three Months Ended Six Months Ended Interest Rate March 30, 2024 April 1, 2023 March 30, 2024 April 1, 2023 2028 Senior Notes 4.625 % $ 4.8 $ 4.8 $ 9.6 $ 10.0 2029 Senior Notes 3.250 % 8.2 8.2 16.4 17.1 Total $ 13.0 $ 13.0 $ 26.0 $ 27.1

Derivatives

Derivatives	6 Months Ended
	Mar. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives Interest Rate Swaps - Cash Flow Hedge The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate swaps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income (“AOCI”) to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. In fiscal 2019, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023 to hedge a portion of its variable rate debt. On August 25, 2022, the interest rate swap agreement was restructured (consistent with the 2021 Credit Agreement) to convert the benchmark interest rate from LIBOR to the SOFR rate effective September 23, 2022 with a termination date of December 17, 2023. The Company applied the practical and optional expedients in ASC 848, Reference Rate Reform , in evaluating the impact of modifying the contract, which resulted in no change to the accounting for this derivative contract. The notional amount of this swap was $1.0 billion. The restructured interest rate swap fixed the SOFR component of the variable interest rate on $1.0 billion of the notional amount under the 2021 Credit Agreement at 1.23%. The critical terms of the restructured interest rate swap were designed to mirror the terms of the Company’s SOFR-based borrowings under the 2021 Credit Agreement and therefore were highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on $1.0 billion of principal. Therefore, changes in the fair value of the swap were recorded in AOCI. The contract ended during the first quarter of fiscal 2024 and as a result the fair value of this derivative was $0.0 million as of March 30, 2024. On March 23, 2023, the Company entered into two consecutive interest rate swap contracts with the first contract having an effective date of December 17, 2023 and terminating on December 27, 2024, and the second contract having an effective date of December 27, 2024 and terminating on September 25, 2026. The notional amount of these swaps is $500 million, and the first interest rate swap fixes the SOFR component of the variable interest rate at 3.46%, and the second interest rate swap fixes the SOFR component of the variable interest rate at 2.98%. The critical terms of the interest rate swaps are designed to mirror the terms of the Company’s SOFR-based borrowings under the 2021 Credit Agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on $500 million of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of these swaps was an asset position of $14.2 million as of March 30, 2024. Forward Foreign Currency Exchange Contracts and Foreign Currency Option Contracts The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company’s cash and operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The contracts are generally for periods of one year or less. The Company did not elect hedge accounting for these contracts; however, the Company may seek to apply hedge accounting in future scenarios. As of March 30, 2024 the notional amount was $190.3 million. The change in the fair value of these contracts is recognized directly in earnings as a component of other income (expense), net. Realized and unrealized gains and losses from these contracts, which were the only derivative contracts not designated for hedge accounting, for the three and six months ended March 30, 2024 and April 1, 2023, respectively, were as follows: Three Months Ended Six Months Ended March 30, 2024 April 1, 2023 March 30, 2024 April 1, 2023 Amount of realized gain (loss) recognized in income Forward foreign currency contracts $ 0.6 $ (0.3) $ 1.8 $ (2.7) Foreign currency option contracts — (1.3) — (1.5) $ 0.6 $ (1.6) $ 1.8 $ (4.2) Amount of unrealized gain (loss) recognized in income Forward foreign currency contracts $ 6.8 $ — $ (5.8) $ (13.8) Foreign currency option contracts — 0.5 — (7.8) $ 6.8 $ 0.5 $ (5.8) $ (21.6) Amount of gain (loss) recognized in income Total $ 7.4 $ (1.1) $ (4.0) $ (25.8) Financial Instrument Presentation The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the balance sheet as of March 30, 2024: Balance Sheet Location March 30, 2024 September 30, 2023 Assets: Derivative instruments designated as a cash flow hedge: Interest rate swap contracts Prepaid expenses and other current assets $ 7.9 $ 16.2 Interest rate swap contracts Other assets 6.3 10.7 $ 14.2 $ 26.9 Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ 2.9 $ 8.4 $ 2.9 $ 8.4 Liabilities: Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ 0.2 $ — The following table presents the unrealized gain (loss) recognized in AOCI related to interest rate swaps for the following reporting periods: Three Months Ended Six Months Ended March 30, 2024 April 1, 2023 March 30, 2024 April 1, 2023 Amount of gain (loss) recognized in other comprehensive income, net of taxes: Interest rate swaps $ 4.6 $ (6.4) $ (9.6) $ (9.3) Total $ 4.6 $ (6.4) $ (9.6) $ (9.3)

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(12) Commitments and Contingencies Litigation and Related Matters On November 4, 2022, a product liability complaint was filed against the Company in Massachusetts state court by a group of plaintiffs who claim they sustained injuries caused by the BioZorb 3D Bioabsorbable Marker, and additional complaints were subsequently filed alleging similar claims. The BioZorb device is an implantable three-dimensional marker that helps clinicians overcome certain challenges presented by breast conserving cancer surgery (lumpectomy). The complaints allege that the plaintiffs suffered side effects that were not disclosed in the BioZorb instructions for use and make various additional claims related to the design, manufacture and marketing of the device. Complaints have been filed on behalf of 88 plaintiffs, one pending in Massachusetts state court, and the remainder in United States District Court for the District of Massachusetts. Discovery is ongoing. While the Company believes it has valid defenses and plans to vigorously defend its position, litigation can be costly and unpredictable, and at this early stage the Company cannot reasonably assess the outcome of this matter. The Company is a party to various other legal proceedings, claims, governmental and/or regulatory inspections, inquiries and investigations arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings, claims, inspections, inquiries or investigations pending against it, the ultimate resolution of which are reasonably likely based upon management’s assessment, to have a material adverse effect on its financial condition or results of operations. It is possible that future results for any particular quarter or annual period may be materially affected by changes in our assumptions or the effectiveness of our strategies relating to these matters. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies

Net Income (Loss) Per Share

Net Income (Loss) Per Share	6 Months Ended
	Mar. 30, 2024
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income Per Share A reconciliation of basic and diluted share amounts is as follows: Three Months Ended Six Months Ended March 30, April 1, March 30, April 1, Basic weighted average common shares outstanding 235,890 247,730 237,258 247,524 Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units 1,672 2,063 1,630 2,013 Diluted weighted average common shares outstanding 237,562 249,793 238,888 249,537 Weighted-average anti-dilutive shares related to: Outstanding stock options and restricted stock units 1,134 792 1,590 1,211

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Mar. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income: Three Months Ended Six Months Ended March 30, April 1, March 30, April 1, Cost of revenues $ 3.2 $ 2.7 $ 5.9 $ 5.6 Research and development 3.0 3.1 6.2 6.5 Selling and marketing 3.6 3.0 6.9 6.3 General and administrative 16.0 14.4 35.5 25.3 $ 25.8 $ 23.2 $ 54.5 $ 43.7 The Company granted options to purchase 0.6 million and 0.5 million shares of the Company’s common stock during the six months ended March 30, 2024 and April 1, 2023, respectively, with weighted-average exercise prices of $72.27 and $74.59, respectively. There were 4.5 million options outstanding at March 30, 2024 with a weighted-average exercise price of $54.63. The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table: Three Months Ended Six Months Ended March 30, April 1, March 30, April 1, Risk-free interest rate 4.4 % 4.3 % 4.4 % 4.3 % Expected volatility 33.4 % 33.9 % 33.4 % 33.9 % Expected life (in years) 4.8 4.8 4.8 4.8 Dividend yield — — — — Weighted average fair value of options granted $ 26.27 $ 27.42 $ 25.04 $ 25.92 The Company granted 0.7 million and 0.6 million restricted stock units (“RSUs”) during the six months ended March 30, 2024 and April 1, 2023, respectively, with weighted-average grant date fair values of $72.00 and $74.44 per unit, respectively. In addition, the Company granted 0.1 million and 0.1 million performance stock units (“PSUs”) during the six months ended March 30, 2024 and April 1, 2023, respectively, to members of its senior management team, which have a weighted-average grant date fair value of $71.92 and $74.35 per unit, respectively. Each recipient of PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of a three-year performance period, provided that the Company’s defined Return on Invested Capital metrics are achieved. The Company also granted 0.1 million and 0.1 million of FCF PSUs based on a three-year cumulative free cash flow measure (“FCF PSUs”) to members of its senior management team, which had a grant date fair value of $71.92 and $74.35 per unit during the six months ended March 30, 2024 and April 1, 2023, respectively. Each recipient of FCF PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of the three-year measurement period. The PSUs and FCF PSUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense ratably over the required service period based on its estimate of the probable number of shares that will vest upon achieving the measurement criteria. If there is a change in the estimate of the number of shares that are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made. The Company also granted 0.1 million and 0.1 million market-based awards (“MSUs”) to members of its senior management team during the six months ended March 30, 2024 and April 1, 2023, respectively. Each recipient of MSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of a three-year performance period based upon achieving a certain total shareholder return relative to a defined peer group. The MSUs were valued at $88.06 and $97.91 per share using the Monte Carlo simulation model in fiscal 2024 and 2023, respectively. The MSUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense for the MSUs ratably over the service period. At March 30, 2024, there was 1.7 million in aggregate unvested RSUs, PSUs, FCF PSUs and MSUs outstanding. At March 30, 2024, there was $14.4 million and $67.2 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs, PSUs, FCF PSUs and MSUs), respectively, to be recognized over a weighted-average period of 2.4 and 2.0 years, respectively.

Other Balance Sheet Information

Other Balance Sheet Information	3 Months Ended
	Mar. 30, 2024
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information	Other Balance Sheet Information March 30, September 30, Inventories Raw materials $ 277.2 $ 238.6 Work-in-process 63.0 66.3 Finished goods 309.0 312.7 $ 649.2 $ 617.6 Property, plant and equipment Equipment $ 384.8 $ 380.0 Equipment under customer usage agreements 521.4 508.1 Building and improvements 239.0 230.0 Leasehold improvements 41.8 44.4 Land 40.8 41.1 Furniture and fixtures 22.6 19.2 Finance lease right-of-use asset 8.5 8.2 $ 1,258.9 $ 1,231.0 Less – accumulated depreciation and amortization (734.1) (714.0) $ 524.8 $ 517.0

Business Segments and Geographi

Business Segments and Geographic Information	6 Months Ended
	Mar. 30, 2024
Segment Reporting [Abstract]
Business Segments and Geographic Information	Business Segments and Geographic Information The Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges (such as intangible asset amortization expense, and goodwill and intangible asset impairment charges), transaction and integration expenses for acquisitions, restructuring, consolidation and divestiture charges, litigation charges, and other one-time or unusual items. Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three and six months ended March 30, 2024 and April 1, 2023. Segment information is as follows: Three Months Ended Six Months Ended March 30, April 1, March 30, April 1, Total revenues: Diagnostics $ 450.1 $ 464.7 $ 897.9 $ 1,024.0 Breast Health 384.6 385.4 762.3 719.5 GYN Surgical 156.0 144.8 318.2 298.9 Skeletal Health 27.1 31.6 52.5 58.3 $ 1,017.8 $ 1,026.5 $ 2,030.9 $ 2,100.7 Income from operations: Diagnostics $ 71.1 $ 105.3 $ 120.5 $ 256.4 Breast Health 91.7 109.9 193.8 170.4 GYN Surgical 44.3 52.3 87.6 101.0 Skeletal Health 3.3 4.6 6.7 6.7 $ 210.4 $ 272.1 $ 408.6 $ 534.5 Depreciation and amortization: Diagnostics $ 51.5 $ 56.1 $ 117.4 $ 116.0 Breast Health 10.0 12.9 20.3 26.5 GYN Surgical 12.1 11.6 24.1 23.9 Skeletal Health 0.1 0.2 0.3 0.3 $ 73.7 $ 80.8 $ 162.1 $ 166.7 Capital expenditures: Diagnostics $ 19.8 $ 20.2 $ 44.0 $ 36.1 Breast Health 5.4 6.9 14.7 14.1 GYN Surgical 2.5 2.8 6.7 6.7 Skeletal Health 0.3 0.1 0.4 0.2 Corporate — 2.1 0.2 4.1 $ 28.0 $ 32.1 $ 66.0 $ 61.2 March 30, September 30, Identifiable assets: Diagnostics $ 2,520.1 $ 2,596.4 Breast Health 1,212.9 1,170.1 GYN Surgical 1,440.2 1,455.4 Skeletal Health 30.8 33.7 Corporate 3,510.4 3,883.7 $ 8,714.4 $ 9,139.3 The Company had no customers that represented greater than 10% of consolidated revenues during the three and six months ended March 30, 2024 and April 1, 2023. The Company operates in the following major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from the United Kingdom, Germany, France, Spain, Italy and the Netherlands. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East. Revenues by geography as a percentage of total revenues were as follows: Three Months Ended Six Months Ended March 30, April 1, March 30, April 1, United States 74.6 % 74.9 % 74.5 % 75.8 % Europe 13.5 % 14.8 % 13.8 % 14.2 % Asia-Pacific 6.3 % 6.4 % 6.3 % 6.1 % Rest of World 5.6 % 3.9 % 5.4 % 3.9 % 100.0 % 100.0 % 100.0 % 100.0 %

Income Taxes

Income Taxes	6 Months Ended
	Mar. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes In accordance with ASC 740, Income Taxes , each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period. For the three months ended March 30, 2024, the Company recorded income tax expense of $41.6 million resulting in an effective tax rate of 19.7%. For the six months ended March 30, 2024, the Company recorded an income tax benefit of $13.6 million, resulting in an effective tax rate of (3.4)%. The effective tax rate for the three months ended March 30, 2024 was lower than the U.S. statutory tax rate primarily due to the U.S. deduction for foreign derived intangible income and the geographic mix of income earned by the Company’s international subsidiaries, which are generally taxed at rates lower than the U.S. statutory tax rate. The effective tax rate for the six months ended March 30, 2024 was lower than the U.S. statutory tax rate primarily due to a discrete tax benefit of $107.2 million related to a worthless stock deduction on the investment in one of the Company’s international subsidiaries recorded in the first quarter of fiscal 2024, the U.S. deduction for foreign derived intangible income, and the geographic mix of income earned by the Company’s international subsidiaries, which are generally taxed at rates lower than the U.S. statutory tax rate. The Company recorded income tax expense of $60.8 million and $112.5 million for the three and six months ended April 1, 2023, resulting in effective tax rates of 21.8% and 21.7%, respectively. The effective tax rates for the three and six months ended April 1, 2023 were higher than the U.S. statutory tax rate primarily due to increases to income tax reserves, the global intangible low-taxed income inclusion, and state income taxes, partially offset by the impact of the U.S. deduction for foreign derived intangible income, the geographic mix of income earned by the Company’s international subsidiaries, which are generally taxed at rates lower than the U.S. statutory tax rate, and federal and state tax credits. Non-Income Tax Matters The Company is subject to tax examinations for value added, sales-based, payroll and other non-income tax items. A number of these examinations are ongoing in various jurisdictions. The Company takes certain non-income tax positions in the jurisdictions in which it operates and records loss contingencies pursuant to ASC 450. Such amounts were not material for any of the periods presented. In the normal course of business, the Company's positions and conclusions related to its non-income tax positions could be challenged, resulting in assessments by governmental authorities. While the Company believes estimated losses previously recorded are reasonable, certain audits are still ongoing and additional charges could be recorded in the future.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	6 Months Ended
	Mar. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Intangible Assets Intangible assets consisted of the following: Description As of March 30, 2024 As of September 30, 2023 Gross Accumulated Gross Accumulated Acquired intangible assets: Developed technology $ 4,389.4 $ 3,742.2 $ 4,411.0 $ 3,649.5 In-process research and development 21.9 — 25.7 — Customer relationships 601.0 561.7 600.0 550.6 Trade names 253.0 221.0 253.6 212.8 Total acquired intangible assets $ 5,265.3 $ 4,524.9 $ 5,290.3 $ 4,412.9 Internal-use software 25.5 19.4 24.0 17.8 Capitalized software embedded in products 29.0 23.6 27.7 22.7 Total intangible assets $ 5,319.8 $ 4,567.9 $ 5,342.0 $ 4,453.4 The estimated remaining amortization expense of the Company’s acquired intangible assets as of March 30, 2024 for each of the five succeeding fiscal years was as follows: Remainder of Fiscal 2024 $ 97.8 Fiscal 2025 $ 183.2 Fiscal 2026 $ 153.3 Fiscal 2027 $ 66.3 Fiscal 2028 $ 63.2 During the second quarter of fiscal 2024, in connection with commencing its company-wide annual strategic planning process, the Company identified indicators of impairment in its BioZorb product line, which was part of the Focal acquisition. As a result, the Company performed an undiscounted cash flow analysis pursuant to ASC 360, Property, Plant and Equipment - Overall, to determine if the cash flows expected to be generated by the BioZorb product line over the remaining estimated useful life of the primary asset were sufficient to recover the carrying value of the asset group. Based on this analysis the undiscounted cash flows were not sufficient to recover the carrying value of the long-lived assets. Therefore, the Company was required to perform Step 3 of the impairment test and determine the fair value of the asset group. To estimate the fair value of the asset group, the Company utilized the income approach, which is based on a discounted cash flow (DCF) analysis and calculated the fair value by estimating the after-tax cash flows attributable to the asset group and then discounting the after-tax cash flows to present value using a risk-adjusted discount rate. Based on this analysis, the fair value of the BioZorb asset group was below its carrying value and the Company recorded an impairment charge of $26.8 million during the second quarter of fiscal 2024. The impairment charge was allocated to the long-lived assets on a pro-rata basis as follows: $25.9 million to developed technology and $0.9 million to trade names, which reduced the carrying value of the assets to $13.9 million and $0.5 million respectively. The Company also re-evaluated the remaining useful lives of the intangible assets and concluded no changes were necessary. During the first quarter of fiscal 2024, the Company assessed its only in-process research and development intangible asset from its Mobidiag acquisition for impairment. The Company determined the fair value of this indefinite lived asset utilizing the DCF model and recorded a $4.3 million impairment charge, reducing the fair value of this asset to $22.4 million. The reduction in fair value of this asset was primarily due to a reduction in forecasted revenues and a delay in the timing of completing the project. In addition, the Company determined that the useful life of the customer relationship and trade name intangible assets from its Mobidiag acquisition should be shortened and recorded accelerated amortization expense of $7.3 million to bring the net carrying values to zero.

Product Warranties

Product Warranties	6 Months Ended
	Mar. 30, 2024
Guarantees [Abstract]
Product Warranties	Product Warranties Product warranty activity was as follows: Balance at Provisions Settlements/ Balance at Six Months Ended: March 30, 2024 $ 8.3 $ 5.3 $ (4.4) $ 9.2 April 1, 2023 $ 8.0 $ 3.3 $ (3.8) $ 7.5

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Mar. 30, 2024
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Income (Loss) The following tables summarize the changes in accumulated balances of other comprehensive income (loss) for the periods presented: Three Months Ended March 30, 2024 Six Months Ended March 30, 2024 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Beginning Balance $ (125.0) $ 0.3 $ 5.9 $ (118.8) $ (168.0) $ 0.3 $ 20.1 $ (147.6) Other comprehensive income (loss) before reclassifications (22.8) — 4.6 (18.2) 20.2 — (9.6) 10.6 Ending Balance $ (147.8) $ 0.3 $ 10.5 $ (137.0) $ (147.8) $ 0.3 $ 10.5 $ (137.0) Three Months Ended April 1, 2023 Six Months Ended April 1, 2023 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Beginning Balance $ (153.4) $ (0.3) $ 26.4 $ (127.3) $ (267.2) $ (0.3) $ 29.3 $ (238.2) Other comprehensive income (loss) before reclassifications 15.3 — (6.4) 8.9 129.1 — (9.3) 119.8 Ending Balance $ (138.1) $ (0.3) $ 20.0 $ (118.4) $ (138.1) $ (0.3) $ 20.0 $ (118.4)

Share Repurchase

Share Repurchase	6 Months Ended
	Mar. 30, 2024
Equity [Abstract]
Share Repurchase	Share Repurchase On September 22, 2022, the Board of Directors authorized a stock repurchase program, with a five-year term, to repurchase up to $1.0 billion of the Company’s outstanding common stock, effective as of the close of trading September 23, 2022. This repurchase program replaced the previous $1.0 billion authorization. Exclusive of shares repurchased pursuant to the accelerated shares repurchase agreement described below, during the three and six months ended March 30, 2024, the Company repurchased 0.0 million and 2.2 million shares of its common stock under the authorization for total consideration of $0.0 million and $150.0 million, respectively. As of March 30, 2024, $348.6 million remained available under this authorization. On November 6, 2023, the Board of Directors authorized the Company to repurchase up to $500 million of the Company’s outstanding shares pursuant to an accelerated share repurchase (“ASR”) agreement. On November 15, 2023, the Company executed the ASR agreement with Goldman Sachs & Co. (“Goldman Sachs”) pursuant to which the Company agreed to repurchase $500 million of the Company’s common stock. In connection with the launch of the ASR, on November 17, 2023, the Company paid Goldman Sachs an aggregate of $500 million and received approximately 5.6 million shares of the Company’s common stock, representing 80% of the transaction value based on the Company’s closing share price on November 14, 2023. On February 27, 2024, the ASR agreement was completed, and the Company received an additional 1.4 million shares for the final settlement. This final settlement was based on the total transaction value and the volume-weighted average share price of the Company’s common stock during the term of the agreement.

New Accounting Pronouncements

New Accounting Pronouncements	6 Months Ended
	Mar. 30, 2024
Accounting Policies [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended						6 Months Ended
	Mar. 30, 2024	Dec. 30, 2023	Sep. 30, 2023	Jul. 01, 2023	Apr. 01, 2023	Dec. 31, 2022	Mar. 30, 2024	Apr. 01, 2023
Pay vs Performance Disclosure
Net Income (Loss) Attributable to Parent	$ 169.9	$ 246.5	$ 90.6	$ (40.5)	$ 218.5	$ 187.4	$ 416.4	$ 405.9

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	6 Months Ended
	Mar. 30, 2024 shares	Mar. 30, 2024 shares
Christiana Stamoulis [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		During the second quarter of fiscal 2024, Christiana Stamoulis, a member of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act on February 16, 2024 to sell up to 16,441 shares of our common stock (following the exercise of options) between May 21, 2024 and January 3, 2025, the date this plan expires. The trading plan will cease upon the earlier of January 3, 2025 or the sale of all shares subject to the trading plan.
Name	Christiana Stamoulis
Title	Board of Directors
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	February 16, 2024
Arrangement Duration	227 days
Aggregate Available	16,441	16,441
Other Directors or Executive Officers [Member]
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted		false
Non-Rule 10b5-1 Arrangement Adopted		false
Rule 10b5-1 Arrangement Terminated		false
Non-Rule 10b5-1 Arrangement Terminated		false

Revenue from Contract with Cust

Revenue from Contract with Customer (Policies)	6 Months Ended
	Mar. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue	(2) Revenue The Company accounts for revenue pursuant to ASC 606, Revenue from Contracts with Customer (ASC 606) and generates revenue from the sale of its products, primarily medical imaging systems and related components and software, diagnostic tests and assays and surgical disposable products, and related services, which are primarily support and maintenance services on its medical imaging systems, and to a lesser extent installation, training and repairs. In addition, the Company generates service revenue from performing laboratory testing services through its Biotheranostics CLIA laboratory, which is included in its Molecular Diagnostics business. The Company’s products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors and resellers. Revenue is recorded net of sales tax. The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis: Three Months Ended March 30, 2024 Three Months Ended April 1, 2023 Business ( in millions ) United States International Total United States International Total Diagnostics: Cytology & Perinatal $ 70.7 $ 49.8 $ 120.5 $ 69.0 $ 42.9 $ 111.9 Molecular Diagnostics 255.4 67.3 322.7 263.0 79.2 342.2 Blood Screening 6.9 — 6.9 10.6 — 10.6 Total $ 333.0 $ 117.1 $ 450.1 $ 342.6 $ 122.1 $ 464.7 Breast Health: Breast Imaging $ 234.9 $ 71.8 $ 306.7 $ 233.5 $ 78.0 $ 311.5 Interventional Breast Solutions 60.4 17.5 77.9 59.8 14.1 73.9 Total $ 295.3 $ 89.3 $ 384.6 $ 293.3 $ 92.1 $ 385.4 GYN Surgical $ 115.6 $ 40.4 $ 156.0 $ 113.6 $ 31.2 $ 144.8 Skeletal Health $ 15.5 $ 11.6 $ 27.1 $ 19.2 $ 12.4 $ 31.6 $ 759.4 $ 258.4 $ 1,017.8 $ 768.7 $ 257.8 $ 1,026.5 Six Months Ended March 30, 2024 Six Months Ended April 1, 2023 Business (in millions) United States International Total United States International Total Diagnostics: Cytology & Perinatal $ 140.5 $ 100.0 $ 240.5 $ 147.1 $ 91.5 $ 238.6 Molecular Diagnostics 502.9 139.6 642.5 591.3 176.2 767.5 Blood Screening 14.9 — 14.9 17.9 — 17.9 Total $ 658.3 $ 239.6 $ 897.9 $ 756.3 $ 267.7 $ 1,024.0 Breast Health: Breast Imaging $ 463.3 $ 144.8 $ 608.1 $ 445.8 $ 130.1 $ 575.9 Interventional Breast Solutions 121.5 32.7 154.2 117.5 26.1 143.6 Total $ 584.8 $ 177.5 $ 762.3 $ 563.3 $ 156.2 $ 719.5 GYN Surgical $ 240.8 $ 77.4 $ 318.2 $ 236.7 $ 62.2 $ 298.9 Skeletal Health $ 29.2 $ 23.3 $ 52.5 $ 36.0 $ 22.3 $ 58.3 $ 1,513.1 $ 517.8 $ 2,030.9 $ 1,592.3 $ 508.4 $ 2,100.7 Three Months Ended Six Months Ended Geographic Regions ( in millions ) March 30, 2024 April 1, 2023 March 30, 2024 April 1, 2023 United States $ 759.4 $ 768.7 $ 1,513.1 $ 1,592.3 Europe 137.0 151.5 279.8 298.8 Asia-Pacific 64.4 65.2 128.2 129.1 Rest of World 57.0 41.1 109.8 80.5 $ 1,017.8 $ 1,026.5 $ 2,030.9 $ 2,100.7 The following table provides revenue recognized by source: Three Months Ended Six Months Ended Revenue by type (in millions) March 30, 2024 April 1, 2023 March 30, 2024 April 1, 2023 Disposables $ 618.9 $ 626.5 $ 1,247.8 $ 1,354.3 Capital equipment, components and software 209.1 210.9 408.2 369.5 Service 185.0 183.0 363.8 366.2 Other 4.8 6.1 11.1 10.7 $ 1,017.8 $ 1,026.5 $ 2,030.9 $ 2,100.7 The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company’s products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains the use of and substantially all of the remaining benefits of the product. As such, the Company’s performance obligation related to product sales is satisfied at a point in time. Revenue from support and maintenance contracts, extended warranty, and professional services for installation, training and repairs is recognized over time based on the period contracted or as the services are performed as these methods represent a faithful depiction of the transfer of goods and services. The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction and is most often equal to the transaction price in the contract. Payment terms are typically 30 days in the U.S. but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within costs of product revenue when the corresponding revenue is recognized. The Company also places instruments (or equipment) at customer sites but retains title to the instrument. The customer has the right to use the instrument for a period of time, and the Company recovers the cost of providing the instrument through the sales of disposables, namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements include an embedded lease, which is generally an operating lease, for the right to use an instrument and no instrument revenue is recognized at the time of instrument delivery. The Company recognizes a portion of the revenue allocated to the embedded lease concurrent with the sale of disposables over the term of the agreement. Revenue from laboratory testing services, which is generated by the Company’s Biotheranostics business, is recognized based upon contracted amounts with payors and historical cash collection experience for the same test or same payor group. Revenue is recognized once the laboratory services have been performed, the results have been delivered to the ordering physician, the payor has been identified, and insurance has been verified. The estimated timeframes for cash collection are three months for Medicare payors, six months for Medicare Advantage payors, and nine months for commercial payors. Generally, the contracts for capital equipment include multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. The Company determines its best estimate of standalone selling price using average selling prices over 3- to 12-month periods of data depending on the products or nature of the services coupled with current market considerations. If the product or service does not have a history of sales or if sales volume is not sufficient, the Company relies on prices set by its pricing committees or applicable marketing department adjusted for expected discounts. Variable Consideration The Company exercises judgment in estimating variable consideration, which includes volume discounts, sales rebates, product returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability. The Company bases its estimates for volume discounts and sales rebates on historical information to the extent it is reasonable to be used as a predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts. The Company’s contracts for the sale of capital equipment and related components, and assays and tests typically do not provide the right to return product, however, its contracts for the sale of its GYN Surgical and Interventional Breast Solutions surgical handpieces provide for a right of return for a limited period of time. In general, estimates of variable consideration and constraints are not material to the Company’s financial statements. Remaining Performance Obligations As of March 30, 2024, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $813.5 million. These remaining performance obligations primarily relate to support and maintenance obligations and extended warranty in the Company’s Breast Health and Skeletal Health reportable segments. The Company expects to recognize approximately 26% of this amount as revenue in fiscal 2024, 37% in fiscal 2025, 21% in fiscal 2026, 10% in fiscal 2027, and 6% thereafter. As permitted, the Company does not include remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above. Contract Assets and Liabilities The Company discloses accounts receivable separately in the Consolidated Balance Sheets at their net realizable value. Contract assets primarily relate to the Company’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial. Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations within the Company’s Breast Health and Skeletal Health reportable segments. Contract liabilities are classified as other current liabilities and other long-term liabilities in the Consolidated Balance Sheets. The Company recognized revenue of $37.1 million and $101.6 million in the three and six months ended March 30, 2024, respectively, that was included in the contract liability balance at September 30, 2023. The Company recognized $34.5 million and $101.3 million in the three and six months ended April 1, 2023, respectively, that was included in the contract liability at September 24, 2022. Practical Expedients The Company applies a practical expedient to expense costs to obtain a contract with a customer as incurred when the amortization period would have been one year or less. These costs solely comprise sales commissions and typically the commissions are incurred at the time of shipment of product and upon billings for support and maintenance contracts.

New Accounting Pronouncements (

New Accounting Pronouncements (Policies)	6 Months Ended
	Mar. 30, 2024
Accounting Policies [Abstract]
New Accounting Pronouncements	In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures . The guidance requires entities to provide enhanced disclosures about significant segment expenses. For entities that have adopted the amendments in Update 2023-07, the updated guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-07 on its consolidated financial position and results of operations. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures . The FASB issued this Update to enhance income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its consolidated financial position and results of operations. In March 2024, the SEC issued its final climate disclosure rule, which requires the disclosure of Scope 1 and Scope 2 greenhouse gas emissions and other climate-related topics in annual reports and registration statements, when material. Disclosure requirements were to begin phasing in for fiscal years beginning on or after January 1, 2025, however on April 4, 2024, the SEC issued an order staying the rule is pending the completion of an ongoing judicial review. The Company is monitoring SEC developments and evaluating the impact of the new rule to its financial statements.

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Mar. 30, 2024
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis: Three Months Ended March 30, 2024 Three Months Ended April 1, 2023 Business ( in millions ) United States International Total United States International Total Diagnostics: Cytology & Perinatal $ 70.7 $ 49.8 $ 120.5 $ 69.0 $ 42.9 $ 111.9 Molecular Diagnostics 255.4 67.3 322.7 263.0 79.2 342.2 Blood Screening 6.9 — 6.9 10.6 — 10.6 Total $ 333.0 $ 117.1 $ 450.1 $ 342.6 $ 122.1 $ 464.7 Breast Health: Breast Imaging $ 234.9 $ 71.8 $ 306.7 $ 233.5 $ 78.0 $ 311.5 Interventional Breast Solutions 60.4 17.5 77.9 59.8 14.1 73.9 Total $ 295.3 $ 89.3 $ 384.6 $ 293.3 $ 92.1 $ 385.4 GYN Surgical $ 115.6 $ 40.4 $ 156.0 $ 113.6 $ 31.2 $ 144.8 Skeletal Health $ 15.5 $ 11.6 $ 27.1 $ 19.2 $ 12.4 $ 31.6 $ 759.4 $ 258.4 $ 1,017.8 $ 768.7 $ 257.8 $ 1,026.5 Six Months Ended March 30, 2024 Six Months Ended April 1, 2023 Business (in millions) United States International Total United States International Total Diagnostics: Cytology & Perinatal $ 140.5 $ 100.0 $ 240.5 $ 147.1 $ 91.5 $ 238.6 Molecular Diagnostics 502.9 139.6 642.5 591.3 176.2 767.5 Blood Screening 14.9 — 14.9 17.9 — 17.9 Total $ 658.3 $ 239.6 $ 897.9 $ 756.3 $ 267.7 $ 1,024.0 Breast Health: Breast Imaging $ 463.3 $ 144.8 $ 608.1 $ 445.8 $ 130.1 $ 575.9 Interventional Breast Solutions 121.5 32.7 154.2 117.5 26.1 143.6 Total $ 584.8 $ 177.5 $ 762.3 $ 563.3 $ 156.2 $ 719.5 GYN Surgical $ 240.8 $ 77.4 $ 318.2 $ 236.7 $ 62.2 $ 298.9 Skeletal Health $ 29.2 $ 23.3 $ 52.5 $ 36.0 $ 22.3 $ 58.3 $ 1,513.1 $ 517.8 $ 2,030.9 $ 1,592.3 $ 508.4 $ 2,100.7 Three Months Ended Six Months Ended Geographic Regions ( in millions ) March 30, 2024 April 1, 2023 March 30, 2024 April 1, 2023 United States $ 759.4 $ 768.7 $ 1,513.1 $ 1,592.3 Europe 137.0 151.5 279.8 298.8 Asia-Pacific 64.4 65.2 128.2 129.1 Rest of World 57.0 41.1 109.8 80.5 $ 1,017.8 $ 1,026.5 $ 2,030.9 $ 2,100.7 The following table provides revenue recognized by source: Three Months Ended Six Months Ended Revenue by type (in millions) March 30, 2024 April 1, 2023 March 30, 2024 April 1, 2023 Disposables $ 618.9 $ 626.5 $ 1,247.8 $ 1,354.3 Capital equipment, components and software 209.1 210.9 408.2 369.5 Service 185.0 183.0 363.8 366.2 Other 4.8 6.1 11.1 10.7 $ 1,017.8 $ 1,026.5 $ 2,030.9 $ 2,100.7

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Mar. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Assets and Liabilities Measured on Recurring Basis	Fair Value at Reporting Date Using Fair Value Quoted Prices in Significant Significant March 30, 2024 Assets: Money market mutual funds $ 410.2 $ 410.2 $ — $ — U.S. Treasury bills 348.1 348.1 — — Commercial paper 49.8 49.8 — — Interest rate swaps 14.2 — 14.2 — Forward foreign currency contracts 2.9 — 2.9 — Total $ 825.2 $ 808.1 $ 17.1 $ — Liabilities: Contingent consideration $ 1.1 $ — $ — $ 1.1 Forward foreign currency contracts 0.2 — 0.2 — Total $ 1.3 $ — $ 0.2 $ 1.1 September 30, 2023 Assets: Interest rate swaps $ 26.9 $ — $ 26.9 $ — Forward foreign currency contracts 8.4 — 8.4 — Total $ 35.3 $ — $ 35.3 $ — Liabilities: Contingent consideration $ 2.0 $ — $ — $ 2.0 Total $ 2.0 $ — $ — $ 2.0 Liabilities Measured and Recorded at Fair Value on a Recurring Basis Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the three and six month periods ended March 30, 2024 and April 1, 2023 were as follows: Three Months Ended Six Months Ended March 30, 2024 April 1, 2023 March 30, 2024 April 1, 2023 Balance at beginning of period $ 3.7 $ 23.4 $ 2.0 $ 23.4 Contingent consideration recorded at acquisition — — — — Fair value adjustments — (12.4) 1.7 (12.4) Payments (2.6) (7.6) (2.6) (7.6) Balance at end of period $ 1.1 $ 3.4 $ 1.1 $ 3.4
Schedule of Cash and Cash Equivalents	The Company’s cash and cash equivalents, including current marketable securities, as of March 30, 2024 are as follows: Valuation Balance Sheet Classification in millions Cost Unrealized Gains Unrealized Losses Fair Value Cash and cash equivalents Investments Cash $ 1,371.9 $ — $ — $ 1,371.9 $ 1,371.9 $ — Money market mutual funds 410.2 — — 410.2 410.2 — U.S. Treasury bills 348.0 0.1 — 348.1 348.1 — Commercial paper 49.8 — — 49.8 49.8 — Total $ 2,179.9 $ 0.1 $ — $ 2,180.0 $ 2,180.0 $ —
Debt Securities, Available-for-Sale	The March 30, 2024 balance of available-for-sale debt securities by contractual maturity is shown in the following table. The fair value of the available-for-sale securities by maturity as of March 30, 2024 and September 30, 2023 are as follows: March 30, 2024 September 30, 2023 in millions Fair Value Fair Value Due in three months or less $ 397.9 $ — Total available-for-sale securities $ 397.9 $ —

Disposition (Tables)

Disposition (Tables)	6 Months Ended
	Mar. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Income from Operation of Disposed Business	The assets and liabilities of the disposed business at the date of disposition were as follows: Assets: Cash $ 33.2 Accounts receivable 4.5 Inventory 16.2 Prepaid expenses and other assets 8.6 Valuation allowance (50.6) Total assets disposed of $ 11.9 Liabilities: Accounts payable $ 3.1 Accrued expenses 5.1 Total liabilities disposed of $ 8.2

Trade Receivables and Allowan_2

Trade Receivables and Allowance for Credit Losses (Tables)	6 Months Ended
	Mar. 30, 2024
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable	The following is a rollforward of the allowance for credit losses as of March 30, 2024 compared to April 1, 2023: Balance at Credit Loss Write-offs, Balance at Six Months Ended March 30, 2024 $ 38.5 $ 5.5 $ (1.3) $ 42.7 April 1, 2023 $ 37.7 $ 1.9 $ (0.2) $ 39.4

Borrowings and Credit Arrange_2

Borrowings and Credit Arrangements (Tables)	6 Months Ended
	Mar. 30, 2024
Debt Disclosure [Abstract]
Company's Borrowings	The Company’s borrowings consisted of the following: March 30, September 30, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ 37.4 $ 287.0 Total current debt obligations $ 37.4 $ 287.0 Long-term debt obligations, net of debt discount and issuance costs: Term Loan $ 1,177.1 $ 1,195.6 2028 Senior Notes 397.2 396.8 2029 Senior Notes 939.8 938.8 Total long-term debt obligations $ 2,514.1 $ 2,531.2 Total debt obligations $ 2,551.5 $ 2,818.2
Schedule of Line of Credit Facilities	Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2021 Credit Agreement were as follows: Three Months Ended Six Months Ended March 30, 2024 April 1, 2023 March 30, 2024 April 1, 2023 Interest expense $ 21.2 $ 22.5 $ 43.8 $ 42.9 Weighted average interest rate 6.43 % 5.74 % 6.43 % 5.39 % Interest rate at end of period 6.43 % 5.91 % 6.43 % 5.91 %
Schedule Of Interest Expense Under Convertible Notes	Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows: Three Months Ended Six Months Ended Interest Rate March 30, 2024 April 1, 2023 March 30, 2024 April 1, 2023 2028 Senior Notes 4.625 % $ 4.8 $ 4.8 $ 9.6 $ 10.0 2029 Senior Notes 3.250 % 8.2 8.2 16.4 17.1 Total $ 13.0 $ 13.0 $ 26.0 $ 27.1

Derivatives (Tables)

Derivatives (Tables)	6 Months Ended
	Mar. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments, Gain (Loss)	Three Months Ended Six Months Ended March 30, 2024 April 1, 2023 March 30, 2024 April 1, 2023 Amount of realized gain (loss) recognized in income Forward foreign currency contracts $ 0.6 $ (0.3) $ 1.8 $ (2.7) Foreign currency option contracts — (1.3) — (1.5) $ 0.6 $ (1.6) $ 1.8 $ (4.2) Amount of unrealized gain (loss) recognized in income Forward foreign currency contracts $ 6.8 $ — $ (5.8) $ (13.8) Foreign currency option contracts — 0.5 — (7.8) $ 6.8 $ 0.5 $ (5.8) $ (21.6) Amount of gain (loss) recognized in income Total $ 7.4 $ (1.1) $ (4.0) $ (25.8)
Schedule of Derivative Assets at Fair Value	The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the balance sheet as of March 30, 2024: Balance Sheet Location March 30, 2024 September 30, 2023 Assets: Derivative instruments designated as a cash flow hedge: Interest rate swap contracts Prepaid expenses and other current assets $ 7.9 $ 16.2 Interest rate swap contracts Other assets 6.3 10.7 $ 14.2 $ 26.9 Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ 2.9 $ 8.4 $ 2.9 $ 8.4 Liabilities: Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ 0.2 $ —
Schedule of Unrealized Loss Recognized in AOCI	The following table presents the unrealized gain (loss) recognized in AOCI related to interest rate swaps for the following reporting periods: Three Months Ended Six Months Ended March 30, 2024 April 1, 2023 March 30, 2024 April 1, 2023 Amount of gain (loss) recognized in other comprehensive income, net of taxes: Interest rate swaps $ 4.6 $ (6.4) $ (9.6) $ (9.3) Total $ 4.6 $ (6.4) $ (9.6) $ (9.3)

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	6 Months Ended
	Mar. 30, 2024
Earnings Per Share [Abstract]
Reconciliation of Basic and Diluted Share Amounts	A reconciliation of basic and diluted share amounts is as follows: Three Months Ended Six Months Ended March 30, April 1, March 30, April 1, Basic weighted average common shares outstanding 235,890 247,730 237,258 247,524 Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units 1,672 2,063 1,630 2,013 Diluted weighted average common shares outstanding 237,562 249,793 238,888 249,537 Weighted-average anti-dilutive shares related to: Outstanding stock options and restricted stock units 1,134 792 1,590 1,211

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Mar. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation Expense in Consolidated Statements of Operations	The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income: Three Months Ended Six Months Ended March 30, April 1, March 30, April 1, Cost of revenues $ 3.2 $ 2.7 $ 5.9 $ 5.6 Research and development 3.0 3.1 6.2 6.5 Selling and marketing 3.6 3.0 6.9 6.3 General and administrative 16.0 14.4 35.5 25.3 $ 25.8 $ 23.2 $ 54.5 $ 43.7
Weighted-Average Assumptions Utilized to Value Stock Options	The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table: Three Months Ended Six Months Ended March 30, April 1, March 30, April 1, Risk-free interest rate 4.4 % 4.3 % 4.4 % 4.3 % Expected volatility 33.4 % 33.9 % 33.4 % 33.9 % Expected life (in years) 4.8 4.8 4.8 4.8 Dividend yield — — — — Weighted average fair value of options granted $ 26.27 $ 27.42 $ 25.04 $ 25.92

Other Balance Sheet Informati_2

Other Balance Sheet Information (Tables)	6 Months Ended
	Mar. 30, 2024
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information of Inventories	March 30, September 30, Inventories Raw materials $ 277.2 $ 238.6 Work-in-process 63.0 66.3 Finished goods 309.0 312.7 $ 649.2 $ 617.6
Other Balance Sheet Information of Property, Plant and Equipment	Property, plant and equipment Equipment $ 384.8 $ 380.0 Equipment under customer usage agreements 521.4 508.1 Building and improvements 239.0 230.0 Leasehold improvements 41.8 44.4 Land 40.8 41.1 Furniture and fixtures 22.6 19.2 Finance lease right-of-use asset 8.5 8.2 $ 1,258.9 $ 1,231.0 Less – accumulated depreciation and amortization (734.1) (714.0) $ 524.8 $ 517.0

Business Segments and Geograp_2

Business Segments and Geographic Information (Tables)	6 Months Ended
	Mar. 30, 2024
Segment Reporting [Abstract]
Segment Information	egment information is as follows: Three Months Ended Six Months Ended March 30, April 1, March 30, April 1, Total revenues: Diagnostics $ 450.1 $ 464.7 $ 897.9 $ 1,024.0 Breast Health 384.6 385.4 762.3 719.5 GYN Surgical 156.0 144.8 318.2 298.9 Skeletal Health 27.1 31.6 52.5 58.3 $ 1,017.8 $ 1,026.5 $ 2,030.9 $ 2,100.7 Income from operations: Diagnostics $ 71.1 $ 105.3 $ 120.5 $ 256.4 Breast Health 91.7 109.9 193.8 170.4 GYN Surgical 44.3 52.3 87.6 101.0 Skeletal Health 3.3 4.6 6.7 6.7 $ 210.4 $ 272.1 $ 408.6 $ 534.5 Depreciation and amortization: Diagnostics $ 51.5 $ 56.1 $ 117.4 $ 116.0 Breast Health 10.0 12.9 20.3 26.5 GYN Surgical 12.1 11.6 24.1 23.9 Skeletal Health 0.1 0.2 0.3 0.3 $ 73.7 $ 80.8 $ 162.1 $ 166.7 Capital expenditures: Diagnostics $ 19.8 $ 20.2 $ 44.0 $ 36.1 Breast Health 5.4 6.9 14.7 14.1 GYN Surgical 2.5 2.8 6.7 6.7 Skeletal Health 0.3 0.1 0.4 0.2 Corporate — 2.1 0.2 4.1 $ 28.0 $ 32.1 $ 66.0 $ 61.2 March 30, September 30, Identifiable assets: Diagnostics $ 2,520.1 $ 2,596.4 Breast Health 1,212.9 1,170.1 GYN Surgical 1,440.2 1,455.4 Skeletal Health 30.8 33.7 Corporate 3,510.4 3,883.7 $ 8,714.4 $ 9,139.3
Revenues by Geography	Revenues by geography as a percentage of total revenues were as follows: Three Months Ended Six Months Ended March 30, April 1, March 30, April 1, United States 74.6 % 74.9 % 74.5 % 75.8 % Europe 13.5 % 14.8 % 13.8 % 14.2 % Asia-Pacific 6.3 % 6.4 % 6.3 % 6.1 % Rest of World 5.6 % 3.9 % 5.4 % 3.9 % 100.0 % 100.0 % 100.0 % 100.0 %

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	6 Months Ended
	Mar. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following: Description As of March 30, 2024 As of September 30, 2023 Gross Accumulated Gross Accumulated Acquired intangible assets: Developed technology $ 4,389.4 $ 3,742.2 $ 4,411.0 $ 3,649.5 In-process research and development 21.9 — 25.7 — Customer relationships 601.0 561.7 600.0 550.6 Trade names 253.0 221.0 253.6 212.8 Total acquired intangible assets $ 5,265.3 $ 4,524.9 $ 5,290.3 $ 4,412.9 Internal-use software 25.5 19.4 24.0 17.8 Capitalized software embedded in products 29.0 23.6 27.7 22.7 Total intangible assets $ 5,319.8 $ 4,567.9 $ 5,342.0 $ 4,453.4
Schedule of Estimated Amortization Expense	The estimated remaining amortization expense of the Company’s acquired intangible assets as of March 30, 2024 for each of the five succeeding fiscal years was as follows: Remainder of Fiscal 2024 $ 97.8 Fiscal 2025 $ 183.2 Fiscal 2026 $ 153.3 Fiscal 2027 $ 66.3 Fiscal 2028 $ 63.2 During the second quarter of fiscal 2024, in connection with commencing its company-wide annual strategic planning process, the Company identified indicators of impairment in its BioZorb product line, which was part of the Focal acquisition. As a result, the Company performed an undiscounted cash flow analysis pursuant to ASC 360, Property, Plant and Equipment - Overall, to determine if the cash flows expected to be generated by the BioZorb product line over the remaining estimated useful life of the primary asset were sufficient to recover the carrying value of the asset group. Based on this analysis the undiscounted cash flows were not sufficient to recover the carrying value of the long-lived assets. Therefore, the Company was required to perform Step 3 of the impairment test and determine the fair value of the asset group. To estimate the fair value of the asset group, the Company utilized the income approach, which is based on a discounted cash flow (DCF) analysis and calculated the fair value by estimating the after-tax cash flows attributable to the asset group and then discounting the after-tax cash flows to present value using a risk-adjusted discount rate. Based on this analysis, the fair value of the BioZorb asset group was below its carrying value and the Company recorded an impairment charge of $26.8 million during the second quarter of fiscal 2024. The impairment charge was allocated to the long-lived assets on a pro-rata basis as follows: $25.9 million to developed technology and $0.9 million to trade names, which reduced the carrying value of the assets to $13.9 million and $0.5 million respectively. The Company also re-evaluated the remaining useful lives of the intangible assets and concluded no changes were necessary. During the first quarter of fiscal 2024, the Company assessed its only in-process research and development intangible asset from its Mobidiag acquisition for impairment. The Company determined the fair value of this indefinite lived asset utilizing the DCF model and recorded a $4.3 million impairment charge, reducing the fair value of this asset to $22.4 million. The reduction in fair value of this asset was primarily due to a reduction in forecasted revenues and a delay in the timing of completing the project. In addition, the Company determined that the useful life of the customer relationship and trade name intangible assets from its Mobidiag acquisition should be shortened and recorded accelerated amortization expense of $7.3 million to bring the net carrying values to zero.

Product Warranties (Tables)

Product Warranties (Tables)	6 Months Ended
	Mar. 30, 2024
Guarantees [Abstract]
Product Warranty Activity	Product warranty activity was as follows: Balance at Provisions Settlements/ Balance at Six Months Ended: March 30, 2024 $ 8.3 $ 5.3 $ (4.4) $ 9.2 April 1, 2023 $ 8.0 $ 3.3 $ (3.8) $ 7.5

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Mar. 30, 2024
Accumulated Other Comprehensive Income [Abstract]
Changes in Accumulated Other Comprehensive Income	The following tables summarize the changes in accumulated balances of other comprehensive income (loss) for the periods presented: Three Months Ended March 30, 2024 Six Months Ended March 30, 2024 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Beginning Balance $ (125.0) $ 0.3 $ 5.9 $ (118.8) $ (168.0) $ 0.3 $ 20.1 $ (147.6) Other comprehensive income (loss) before reclassifications (22.8) — 4.6 (18.2) 20.2 — (9.6) 10.6 Ending Balance $ (147.8) $ 0.3 $ 10.5 $ (137.0) $ (147.8) $ 0.3 $ 10.5 $ (137.0) Three Months Ended April 1, 2023 Six Months Ended April 1, 2023 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Beginning Balance $ (153.4) $ (0.3) $ 26.4 $ (127.3) $ (267.2) $ (0.3) $ 29.3 $ (238.2) Other comprehensive income (loss) before reclassifications 15.3 — (6.4) 8.9 129.1 — (9.3) 119.8 Ending Balance $ (138.1) $ (0.3) $ 20.0 $ (118.4) $ (138.1) $ (0.3) $ 20.0 $ (118.4)

Basis of Presentation (Details)

Basis of Presentation (Details) - Endomagnetics - Subsequent Event $ in Millions	Apr. 26, 2024 USD ($)
Basis of Presentation [Abstract]
Consideration transferred	$ 310
Subsequent Event [Line Items]
Consideration transferred	$ 310

Revenue - Business Revenue (Det

Revenue - Business Revenue (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Disaggregation of Revenue [Line Items]
Revenues	$ 1,017.8	$ 1,026.5	$ 2,030.9	$ 2,100.7
United States
Disaggregation of Revenue [Line Items]
Revenues	759.4	768.7	1,513.1	1,592.3
International
Disaggregation of Revenue [Line Items]
Revenues	258.4	257.8	517.8	508.4
Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	450.1	464.7	897.9	1,024
Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	333	342.6	658.3	756.3
Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	117.1	122.1	239.6	267.7
Diagnostics | Cytology & Perinatal
Disaggregation of Revenue [Line Items]
Revenues	120.5	111.9	240.5	238.6
Diagnostics | Cytology & Perinatal | United States
Disaggregation of Revenue [Line Items]
Revenues	70.7	69	140.5	147.1
Diagnostics | Cytology & Perinatal | International
Disaggregation of Revenue [Line Items]
Revenues	49.8	42.9	100	91.5
Diagnostics | Molecular Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	322.7	342.2	642.5	767.5
Diagnostics | Molecular Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	255.4	263	502.9	591.3
Diagnostics | Molecular Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	67.3	79.2	139.6	176.2
Diagnostics | Blood Screening
Disaggregation of Revenue [Line Items]
Revenues	6.9	10.6	14.9	17.9
Diagnostics | Blood Screening | United States
Disaggregation of Revenue [Line Items]
Revenues	6.9	10.6	14.9	17.9
Diagnostics | Blood Screening | International
Disaggregation of Revenue [Line Items]
Revenues	0	0	0	0
Breast Health
Disaggregation of Revenue [Line Items]
Revenues	384.6	385.4	762.3	719.5
Breast Health | United States
Disaggregation of Revenue [Line Items]
Revenues	295.3	293.3	584.8	563.3
Breast Health | International
Disaggregation of Revenue [Line Items]
Revenues	89.3	92.1	177.5	156.2
Breast Health | Breast Imaging
Disaggregation of Revenue [Line Items]
Revenues	306.7	311.5	608.1	575.9
Breast Health | Breast Imaging | United States
Disaggregation of Revenue [Line Items]
Revenues	234.9	233.5	463.3	445.8
Breast Health | Breast Imaging | International
Disaggregation of Revenue [Line Items]
Revenues	71.8	78	144.8	130.1
Breast Health | Interventional Breast Solutions
Disaggregation of Revenue [Line Items]
Revenues	77.9	73.9	154.2	143.6
Breast Health | Interventional Breast Solutions | United States
Disaggregation of Revenue [Line Items]
Revenues	60.4	59.8	121.5	117.5
Breast Health | Interventional Breast Solutions | International
Disaggregation of Revenue [Line Items]
Revenues	17.5	14.1	32.7	26.1
GYN Surgical
Disaggregation of Revenue [Line Items]
Revenues	156	144.8	318.2	298.9
GYN Surgical | United States
Disaggregation of Revenue [Line Items]
Revenues	115.6	113.6	240.8	236.7
GYN Surgical | International
Disaggregation of Revenue [Line Items]
Revenues	40.4	31.2	77.4	62.2
Skeletal Health
Disaggregation of Revenue [Line Items]
Revenues	27.1	31.6	52.5	58.3
Skeletal Health | United States
Disaggregation of Revenue [Line Items]
Revenues	15.5	19.2	29.2	36
Skeletal Health | International
Disaggregation of Revenue [Line Items]
Revenues	$ 11.6	$ 12.4	$ 23.3	$ 22.3

Revenue - Geographical Revenue

Revenue - Geographical Revenue (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Disaggregation of Revenue [Line Items]
Revenues	$ 1,017.8	$ 1,026.5	$ 2,030.9	$ 2,100.7
United States
Disaggregation of Revenue [Line Items]
Revenues	759.4	768.7	1,513.1	1,592.3
Europe
Disaggregation of Revenue [Line Items]
Revenues	137	151.5	279.8	298.8
Asia-Pacific
Disaggregation of Revenue [Line Items]
Revenues	64.4	65.2	128.2	129.1
Rest of World
Disaggregation of Revenue [Line Items]
Revenues	$ 57	$ 41.1	$ 109.8	$ 80.5

Revenue - Revenue by Type (Deta

Revenue - Revenue by Type (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Disaggregation of Revenue [Line Items]
Revenues	$ 1,017.8	$ 1,026.5	$ 2,030.9	$ 2,100.7
Disposables
Disaggregation of Revenue [Line Items]
Revenues	618.9	626.5	1,247.8	1,354.3
Capital equipment, components and software
Disaggregation of Revenue [Line Items]
Revenues	209.1	210.9	408.2	369.5
Service
Disaggregation of Revenue [Line Items]
Revenues	185	183	363.8	366.2
Other
Disaggregation of Revenue [Line Items]
Revenues	$ 4.8	$ 6.1	$ 11.1	$ 10.7

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Revenue from Contract with Customer [Abstract]
Revenue, Remaining Performance Obligation, Amount	$ 813.5		$ 813.5
Contract with Customer, Liability, Revenue Recognized	$ 37.1	$ 34.5	$ 101.6	$ 101.3

Revenue - Remaining Performance

Revenue - Remaining Performance Obligation (Details)	Mar. 30, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	26%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	37%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	21%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	10%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	6%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year

Leases - Additional Lease Infor

Leases - Additional Lease Information (Details)	3 Months Ended
	Mar. 30, 2024
Leases [Abstract]
Lease revenue as a percentage of total (percentage)	0.03

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Millions	Mar. 30, 2024	Sep. 30, 2023
Assets:
Assets:	$ 2,180
Total	825.2	$ 35.3
Liabilities:
Total	1.3	2
Money Market Funds
Assets:
Assets:	410.2
US Treasury Securities
Assets:
Assets:	348.1
Commercial Paper
Assets:
Assets:	49.8
Interest Rate Swap
Assets:
Total	14.2	26.9
Forward foreign currency contracts
Assets:
Total	2.9	8.4
Prepaid expenses and other current assets | Forward foreign currency contracts | Derivatives not designated as hedging instruments
Assets:
Interest rate swap at fair value	2.9	8.4
Prepaid expenses and other current assets | Forward foreign currency contracts | Derivatives not designated as hedging instruments | Forward foreign currency contracts
Assets:
Interest rate swap at fair value		8.4
Contingent consideration
Liabilities:
Total	1.1	2
Forward foreign currency contracts
Liabilities:
Total	0.2
Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Total	808.1	0
Liabilities:
Total	0	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Money Market Funds
Assets:
Assets:	410.2
Quoted Prices in Active Market for Identical Assets (Level 1) | US Treasury Securities
Assets:
Assets:	348.1
Quoted Prices in Active Market for Identical Assets (Level 1) | Commercial Paper
Assets:
Assets:	49.8
Quoted Prices in Active Market for Identical Assets (Level 1) | Interest Rate Swap
Assets:
Total	0	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Forward foreign currency contracts
Assets:
Total	0	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Contingent consideration
Liabilities:
Total	0	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Forward foreign currency contracts
Liabilities:
Total	0
Significant Other Observable Inputs (Level 2)
Assets:
Total	17.1	35.3
Liabilities:
Total	0.2	0
Significant Other Observable Inputs (Level 2) | Money Market Funds
Assets:
Assets:	0
Significant Other Observable Inputs (Level 2) | US Treasury Securities
Assets:
Assets:	0
Significant Other Observable Inputs (Level 2) | Commercial Paper
Assets:
Assets:	0
Significant Other Observable Inputs (Level 2) | Interest Rate Swap
Assets:
Total	14.2	26.9
Significant Other Observable Inputs (Level 2) | Contingent consideration
Liabilities:
Total	0	0
Significant Unobservable Inputs (Level 3)
Assets:
Total	0	0
Liabilities:
Total	1.1	2
Significant Unobservable Inputs (Level 3) | Money Market Funds
Assets:
Assets:	0
Significant Unobservable Inputs (Level 3) | US Treasury Securities
Assets:
Assets:	0
Significant Unobservable Inputs (Level 3) | Commercial Paper
Assets:
Assets:	0
Significant Unobservable Inputs (Level 3) | Interest Rate Swap
Assets:
Total	0	0
Significant Unobservable Inputs (Level 3) | Forward foreign currency contracts
Assets:
Total	0	0
Significant Unobservable Inputs (Level 3) | Contingent consideration
Liabilities:
Total	1.1	$ 2
Significant Unobservable Inputs (Level 3) | Forward foreign currency contracts
Liabilities:
Total	$ 0

Fair Value Measurements - Roll

Fair Value Measurements - Roll Forward (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Fair Value Disclosures [Abstract]
Beginning balance	$ 3.7	$ 23.4	$ 2	$ 23.4
Contingent consideration recorded at acquisition	0	0	0	0
Fair value adjustments	0	(12.4)	1.7	(12.4)
Payments	(2.6)	(7.6)	(2.6)	(7.6)
Ending balance	$ 1.1	$ 3.4	$ 1.1	$ 3.4

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Mar. 30, 2024	Dec. 30, 2023	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Intangible asset impairment charges				$ 31.1	$ 0
Impairment of intangible assets	$ 0.9		$ 0	5.2	$ 0
Mobidiag | Right of use asset
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Intangible asset impairment charges		$ 12.5
In-process research and development | Mobidiag
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Intangible asset impairment charges		4.3
Intangible Assets, Current	22.4			22.4
Impairment of intangible assets		$ 4.3
Developed technology
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Impairment of intangible assets	25.9
Finite-Lived Intangible Assets, Net	13.9			13.9
Trade Names
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Impairment of intangible assets	0.9
Finite-Lived Intangible Assets, Net	0.5			0.5
2028 Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument	385.9			385.9
2029 Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument	852.6			852.6
Credit Agreement
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Borrowed principal	$ 1,200			$ 1,200
2028 Senior Notes | Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Stated interest rate	4.625%			4.625%
2029 Senior Notes | Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Stated interest rate	3.25%			3.25%

Fair Value Measurements - Cash

Fair Value Measurements - Cash and Cash Equivalents (Details) $ in Millions	6 Months Ended
	Mar. 30, 2024 USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cost	$ 2,179.9
Unrealized Gains	0.1
Unrealized Losses	0
Fair Value	2,180
Cash and Cash Equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value	2,180
Cash
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cost	1,371.9
Unrealized Gains	0
Unrealized Losses	0
Fair Value	1,371.9
Cash | Cash and Cash Equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value	1,371.9
Money Market Funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cost	410.2
Unrealized Gains	0
Unrealized Losses	0
Fair Value	410.2
Money Market Funds | Cash and Cash Equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value	410.2
US Treasury Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cost	348
Unrealized Gains	0.1
Unrealized Losses	0
Fair Value	348.1
US Treasury Securities | Cash and Cash Equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value	348.1
Commercial Paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cost	49.8
Unrealized Gains	0
Unrealized Losses	0
Fair Value	49.8
Commercial Paper | Cash and Cash Equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value	$ 49.8

Fair Value Measurements - Avail

Fair Value Measurements - Available for Sale Debt Securities (Details) - USD ($) $ in Millions	Mar. 30, 2024	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Total available-for-sale securities	$ 397.9	$ 0

Business Combination - Narrativ

Business Combination - Narrative (Details) - USD ($) $ in Millions				3 Months Ended			6 Months Ended
	Jul. 03, 2023	Apr. 03, 2023	Aug. 23, 2020	Mar. 30, 2024	Dec. 30, 2023	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Business Acquisition [Line Items]
Contingent consideration - fair value adjustments				$ 0	$ (1.7)	$ 12.4	$ (1.7)	$ 12.4
Payment for Contingent Consideration Liability, Financing Activities				$ 2.6			$ 2.6	$ 7.6
JW Medical
Business Acquisition [Line Items]
Consideration transferred	$ 6.7
JW Medical | Customer Relationships
Business Acquisition [Line Items]
Intangible assets useful life	5 years
Normedi
Business Acquisition [Line Items]
Consideration transferred		$ 7.7
Contingent consideration		1.1
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships		$ 3
Normedi | Customer Relationships
Business Acquisition [Line Items]
Intangible assets useful life		5 years
Acessa Health
Business Acquisition [Line Items]
Contingent consideration			$ 81.8
Annual incremental revenue growth period			3 years

Strategic Investment (Details)

Strategic Investment (Details) - Maverix Medical LLC $ in Millions	Nov. 13, 2023 USD ($)
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	$ 24.5
Equity Method Investment, Ownership Percentage	45%

Disposition - Additional Inform

Disposition - Additional Information (Details) - USD ($) $ in Millions		3 Months Ended	6 Months Ended
	Sep. 28, 2023	Mar. 30, 2024	Mar. 30, 2024	Apr. 01, 2023	Sep. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Intangible asset impairment charges			$ 31.1	$ 0
Disposed of by Sale | SSI Ultrasound Imaging Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales price	$ 1.9
Cash Divested from Deconsolidation	33.2
Intangible asset impairment charges		$ 51.7
Disposal Group, Including Discontinued Operation, Other Assets	$ 50.6				$ 50.6

Disposition - Schedule of Dispo

Disposition - Schedule of Disposition Related Income Statement Information (Details) - USD ($) $ in Millions	Mar. 30, 2024	Sep. 30, 2023	Sep. 28, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Assets	$ 0	$ 11.9
SSI Ultrasound Imaging Business | Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Cash		33.2	$ 33.2
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net			4.5
Disposal Group, Including Discontinued Operation, Inventory			16.2
Disposal Group, Including Discontinued Operation, Prepaid and Other Assets			8.6
Disposal Group, Including Discontinued Operation, Other Assets		$ (50.6)	(50.6)
Disposal Group, Including Discontinued Operation, Assets			11.9
Disposal Group, Including Discontinued Operation, Accounts Payable			3.1
Disposal Group, Including Discontinued Operation, Accrued Liabilities			5.1
Disposal Group, Including Discontinued Operation, Liabilities			$ 8.2

Trade Receivables and Allowan_3

Trade Receivables and Allowance for Credit Losses (Details) - USD ($) $ in Millions	6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at Beginning of Period	$ 38.5	$ 37.7
Credit Loss	5.5	1.9
Write-offs, Payments and Foreign Exchange	(1.3)	(0.2)
Balance at End of Period	$ 42.7	$ 39.4

Restructuring (Details)

Restructuring (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Mar. 30, 2024	Dec. 30, 2023	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Danbury closure
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Severance Costs	$ 1.3		$ 0.3	$ 1.8	$ 1
Restructuring and Related Cost, Expected Cost	7.5			7.5
Mobidiag
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Restructuring and Related Cost, Accelerated Depreciation		$ 7.2
Other Asset Impairment Charges		12.5
Severance Costs	4	$ 1.8
Restructuring and Related Cost, Expected Cost	$ 12.2			$ 12.2

Borrowings and Credit Arrange_3

Borrowings and Credit Arrangements - Company's Borrowings (Detail) - USD ($) $ in Millions	Mar. 30, 2024	Sep. 30, 2023
Debt Instrument [Line Items]
Current portion of long-term debt	$ 37.4	$ 287
Total long-term debt obligations	2,514.1	2,531.2
Total debt obligations	2,551.5	2,818.2
Term Loan
Debt Instrument [Line Items]
Current portion of long-term debt	37.4	287
Long term debt obligations. excluding convertible notes	1,177.1	1,195.6
2028 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	397.2	396.8
2029 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	$ 939.8	$ 938.8

Borrowings and Credit Arrange_4

Borrowings and Credit Arrangements - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Mar. 30, 2024	Dec. 30, 2023	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023	Aug. 25, 2022	Sep. 27, 2021
Interest Rate Swap, Agreement One
Debt Instrument [Line Items]
Derivative notional amount	$ 1,000			$ 1,000
Variable interest rate	1.23%			1.23%
Interest Rate Swap, Agreement Two
Debt Instrument [Line Items]
Derivative notional amount	$ 500			$ 500
Variable interest rate	3.46%			3.46%
Interest Rate Swap
Debt Instrument [Line Items]
Derivative notional amount						$ 1,000
Variable interest rate						1.23%
Proceeds from swap	$ 2.4		$ 8.6	$ 12	$ 15.2
Secured Term Loan | 2021 Term Loan
Debt Instrument [Line Items]
Senior notes, face amount	1,200			1,200			$ 1,500
Repayments of Debt		$ 250
Revolver | 2021 Revolver
Debt Instrument [Line Items]
Revolving credit facility borrowings							$ 2,000
Senior Notes | 2028 Senior Notes
Debt Instrument [Line Items]
Senior notes, face amount	$ 400			$ 400
Stated interest rate	4.625%			4.625%
Senior Notes | 2029 Senior Notes
Debt Instrument [Line Items]
Stated interest rate	3.25%			3.25%
Senior notes	$ 950			$ 950

Borrowings and Credit Arrange_5

Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details) - Credit Agreement - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Line of Credit Facility [Line Items]
Interest expense	$ 21.2	$ 22.5	$ 43.8	$ 42.9
Weighted average interest rate	6.43%	5.74%	6.43%	5.39%
Interest rate at end of period	6.43%	5.91%	6.43%	5.91%

Borrowings and Credit Arrange_6

Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details) - Senior Notes - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
2028 Senior Notes
Line of Credit Facility [Line Items]
Stated interest rate	4.625%		4.625%
Interest expense	$ 4.8	$ 4.8	$ 9.6	$ 10
2029 Senior Notes
Line of Credit Facility [Line Items]
Stated interest rate	3.25%		3.25%
Interest expense	$ 8.2	8.2	$ 16.4	17.1
Total
Line of Credit Facility [Line Items]
Interest expense	$ 13	$ 13	$ 26	$ 27.1

Derivatives - Additional Inform

Derivatives - Additional Information (Details) - USD ($) $ in Millions	Mar. 30, 2024	Mar. 23, 2023	Aug. 25, 2022
Interest rate swap
Derivative [Line Items]
Derivative notional amount			$ 1,000
Variable interest rate			1.23%
Interest rate swap at fair value	$ 0
Forward Contracts
Derivative [Line Items]
Notational Amount	190.3
Interest Rate Swap, 2023
Derivative [Line Items]
Derivative notional amount		$ 500
Variable interest rate		3.46%
Interest rate swap at fair value	$ 14.2
Interest Rate Swap, 2024
Derivative [Line Items]
Derivative notional amount		$ 500
Variable interest rate		2.98%

Derivatives - Schedule Of Chang

Derivatives - Schedule Of Change in Fair Value Of Derivative Contracts (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Total	$ 7.4	$ (1.1)	$ (4)	$ (25.8)
Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	0.6	(1.6)	1.8	(4.2)
Amount of unrealized gain (loss) recognized in income	6.8	0.5	(5.8)	(21.6)
Forward foreign currency contracts | Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	0.6	(0.3)	1.8	(2.7)
Amount of unrealized gain (loss) recognized in income	6.8	0	(5.8)	(13.8)
Foreign currency option contracts | Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	0	(1.3)	0	(1.5)
Amount of unrealized gain (loss) recognized in income	$ 0	$ 0.5	$ 0	$ (7.8)

Derivatives - Fair Value of Der

Derivatives - Fair Value of Derivative Financial Instruments (Details) - USD ($) $ in Millions	Mar. 30, 2024	Sep. 30, 2023
Interest rate swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	$ 0
Derivative instruments designated as a cash flow hedge | Interest rate swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Asset, Subject to Master Netting Arrangement, before Offset	14.2	$ 26.9
Derivative instruments designated as a cash flow hedge | Interest rate swap | Prepaid expenses and other current assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	7.9	16.2
Derivative instruments designated as a cash flow hedge | Interest rate swap | Other assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	6.3	10.7
Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Asset, Subject to Master Netting Arrangement, before Offset	2.9	8.4
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Prepaid expenses and other current assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	2.9	8.4
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Accrued expenses
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	$ 0.2	$ 0

Derivatives - Gain (Loss) on Fa

Derivatives - Gain (Loss) on Fair Value Hedges Recognized in AOCI (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in other comprehensive income, net of taxes:	$ 4.6	$ (6.4)	$ (9.6)	$ (9.3)
Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in other comprehensive income, net of taxes:	$ 4.6	$ (6.4)	$ (9.6)	$ (9.3)

Net Income (Loss) Per Share - R

Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Earnings Per Share [Line Items]
Basic weighted average common shares outstanding	235,890	247,730	237,258	247,524
Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units	1,672	2,063	1,630	2,013
Diluted weighted average common shares outstanding	237,562	249,793	238,888	249,537
Outstanding Stock Options and stock units
Weighted-average anti-dilutive shares related to:
Weighted-average anti-dilutive shares (in shares)	1,134	792	1,590	1,211

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 25.8	$ 23.2	$ 54.5	$ 43.7
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3.2	2.7	5.9	5.6
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3	3.1	6.2	6.5
Selling and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3.6	3	6.9	6.3
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 16	$ 14.4	$ 35.5	$ 25.3

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Stock option plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)	0.6	0.5
Weighted-average exercise prices (in dollars per share)	$ 72.27	$ 74.59
Share-based compensation, stock options outstanding (in shares)	4.5
Weighted-average exercise price of options outstanding (in dollars per share)	$ 54.63
Unrecognized compensation expense	$ 14.4
Weighted-average period for recognition of unrecognized stock-based compensation, years	2 years 4 months 24 days
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.7	0.6
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 72	$ 74.44
Unrecognized compensation expense	$ 67.2
Weighted-average period for recognition of unrecognized stock-based compensation, years	2 years
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 71.92	$ 74.35
PSU Free Cash Flow [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 71.92	$ 74.35
Minimum eligible percentage to receive target number of shares of company's common stock	0%
Maximum eligible percentage to receive target number of shares of company's common stock	200%
Performance stock units vesting period	3 years
Market Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 88.06	$ 97.91
Minimum eligible percentage to receive target number of shares of company's common stock	0%
Maximum eligible percentage to receive target number of shares of company's common stock	200%
Performance stock units vesting period	3 years
RSU, PSU, MSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)	1.7

Stock-Based Compensation - Weig

Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate	4.40%	4.30%	4.40%	4.30%
Expected volatility	33.40%	33.90%	33.40%	33.90%
Expected life (in years)	4 years 9 months 18 days	4 years 9 months 18 days	4 years 9 months 18 days	4 years 9 months 18 days
Dividend yield	$ 0	$ 0	$ 0	$ 0
Weighted average fair value of options granted	$ 26.27	$ 27.42	$ 25.04	$ 25.92

Other Balance Sheet Informati_3

Other Balance Sheet Information - Inventories (Detail) - USD ($) $ in Millions	Mar. 30, 2024	Sep. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 277.2	$ 238.6
Work-in-process	63	66.3
Finished goods	309	312.7
Inventories	$ 649.2	$ 617.6

Other Balance Sheet Informati_4

Other Balance Sheet Information - Property, Plant and Equipment (Detail) - USD ($) $ in Millions	Mar. 30, 2024	Sep. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Equipment	$ 384.8	$ 380
Equipment under customer usage agreements	521.4	508.1
Building and improvements	239	230
Leasehold improvements	41.8	44.4
Land	40.8	41.1
Furniture and fixtures	22.6	19.2
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	8.5	8.2
Property, plant and equipment, gross	1,258.9	1,231
Less – accumulated depreciation and amortization	(734.1)	(714)
Property, plant and equipment, net	$ 524.8	$ 517

Business Segments and Geograp_3

Business Segments and Geographic Information - Additional Information (Detail)	3 Months Ended			6 Months Ended
	Mar. 30, 2024 USD ($)	Dec. 30, 2023 Segment	Apr. 01, 2023 USD ($)	Mar. 30, 2024 USD ($)	Apr. 01, 2023 USD ($)
Segment Reporting Disclosure [Line Items]
Number of reportable segments | Segment		4
Revenues	$ 1,017,800,000		$ 1,026,500,000	$ 2,030,900,000	$ 2,100,700,000
Intersegment
Segment Reporting Disclosure [Line Items]
Revenues	$ 0		$ 0	$ 0	$ 0

Business Segments and Geograp_4

Business Segments and Geographic Information - Segment Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023	Sep. 30, 2023
Segment Reporting Information [Line Items]
Total revenues	$ 1,017.8	$ 1,026.5	$ 2,030.9	$ 2,100.7
Income (loss) from operations	210.4	272.1	408.6	534.5
Depreciation and amortization	73.7	80.8	162.1	166.7
Capital expenditures	28	32.1	66	61.2
Identifiable assets	8,714.4		8,714.4		$ 9,139.3
Diagnostics
Segment Reporting Information [Line Items]
Total revenues	450.1	464.7	897.9	1,024
Income (loss) from operations	71.1	105.3	120.5	256.4
Depreciation and amortization	51.5	56.1	117.4	116
Capital expenditures	19.8	20.2	44	36.1
Identifiable assets	2,520.1		2,520.1		2,596.4
Breast Health
Segment Reporting Information [Line Items]
Total revenues	384.6	385.4	762.3	719.5
Income (loss) from operations	91.7	109.9	193.8	170.4
Depreciation and amortization	10	12.9	20.3	26.5
Capital expenditures	5.4	6.9	14.7	14.1
Identifiable assets	1,212.9		1,212.9		1,170.1
GYN Surgical
Segment Reporting Information [Line Items]
Total revenues	156	144.8	318.2	298.9
Income (loss) from operations	44.3	52.3	87.6	101
Depreciation and amortization	12.1	11.6	24.1	23.9
Capital expenditures	2.5	2.8	6.7	6.7
Identifiable assets	1,440.2		1,440.2		1,455.4
Skeletal Health
Segment Reporting Information [Line Items]
Total revenues	27.1	31.6	52.5	58.3
Income (loss) from operations	3.3	4.6	6.7	6.7
Depreciation and amortization	0.1	0.2	0.3	0.3
Capital expenditures	0.3	0.1	0.4	0.2
Identifiable assets	30.8		30.8		33.7
Corporate
Segment Reporting Information [Line Items]
Capital expenditures	0	$ 2.1	0.2	$ 4.1
Identifiable assets	$ 3,510.4		$ 3,510.4		$ 3,883.7

Business Segments and Geograp_5

Business Segments and Geographic Information - Revenues by Geography (Detail)	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Schedule Of Geographical Segments [Line Items]
Revenues	100%	100%	100%	100%
United States
Schedule Of Geographical Segments [Line Items]
Revenues	74.60%	74.90%	74.50%	75.80%
Europe
Schedule Of Geographical Segments [Line Items]
Revenues	13.50%	14.80%	13.80%	14.20%
Asia-Pacific
Schedule Of Geographical Segments [Line Items]
Revenues	6.30%	6.40%	6.30%	6.10%
Rest of World
Schedule Of Geographical Segments [Line Items]
Revenues	5.60%	3.90%	5.40%	3.90%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Income Tax Contingency [Line Items]
Company's effective tax rate	19.70%	21.80%	(3.40%)	21.70%
Provision (benefit) for income taxes	$ 41.6	$ 60.8	$ (13.6)	$ 112.5
Foreign Tax Authority
Income Tax Contingency [Line Items]
Provision (benefit) for income taxes	$ 107.2

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail) - USD ($) $ in Millions	Mar. 30, 2024	Sep. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 5,319.8	$ 5,342
Accumulated Amortization	4,567.9	4,453.4
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	4,389.4	4,411
Accumulated Amortization	3,742.2	3,649.5
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	21.9	25.7
Accumulated Amortization	0	0
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	601	600
Accumulated Amortization	561.7	550.6
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	253	253.6
Accumulated Amortization	221	212.8
Total acquired intangible assets
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	5,265.3	5,290.3
Accumulated Amortization	4,524.9	4,412.9
Internal-use software
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	25.5	24
Accumulated Amortization	19.4	17.8
Capitalized software embedded in products
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	29	27.7
Accumulated Amortization	$ 23.6	$ 22.7

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail) $ in Millions	Mar. 30, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of Fiscal 2024	$ 97.8
Fiscal 2025	183.2
Fiscal 2026	153.3
Fiscal 2027	66.3
Fiscal 2028	$ 63.2

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Mar. 30, 2024	Dec. 30, 2023	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Indefinite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 0.9		$ 0	$ 5.2	$ 0
Mobidiag
Indefinite-Lived Intangible Assets [Line Items]
Accelerated amortization		$ 7.3
BioZorb
Indefinite-Lived Intangible Assets [Line Items]
Impairment of intangible assets		26.8
In-process research and development | Mobidiag
Indefinite-Lived Intangible Assets [Line Items]
Impairment of intangible assets		4.3
Intangible Assets, Current	22.4			22.4
Developed technology
Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net	13.9			13.9
Developed technology | BioZorb
Indefinite-Lived Intangible Assets [Line Items]
Impairment of intangible assets		25.9
Trade Names
Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net	$ 0.5			$ 0.5
Trade Names | BioZorb
Indefinite-Lived Intangible Assets [Line Items]
Impairment of intangible assets		$ 0.9

Product Warranties - Product Wa

Product Warranties - Product Warranty Activity (Detail) - USD ($) $ in Millions	6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance at Beginning of Period	$ 8.3	$ 8
Provisions	5.3	3.3
Settlements/ Adjustments	(4.4)	(3.8)
Balance at End of Period	$ 9.2	$ 7.5

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance			$ 5,016.9
Other comprehensive income (loss) before reclassifications	$ (18.2)	$ 8.9	10.6	$ 119.8
Ending balance	4,844.4		4,844.4
Total
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(118.8)	(127.3)	(147.6)	(238.2)
Ending balance	(137)	(118.4)	(137)	(118.4)
Foreign Currency Translation
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(125)	(153.4)	(168)	(267.2)
Other comprehensive income (loss) before reclassifications	(22.8)	15.3	20.2	129.1
Ending balance	(147.8)	(138.1)	(147.8)	(138.1)
Pension Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	0.3	(0.3)	0.3	(0.3)
Other comprehensive income (loss) before reclassifications	0	0	0	0
Ending balance	0.3	(0.3)	0.3	(0.3)
Interest Rate Swap | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	5.9	26.4	20.1	29.3
Other comprehensive income (loss) before reclassifications	4.6	(6.4)	(9.6)	(9.3)
Ending balance	$ 10.5	$ 20	$ 10.5	$ 20

Share Repurchase Share repurcha

Share Repurchase Share repurchase (Details) - USD ($)			3 Months Ended	6 Months Ended
	Feb. 27, 2024	Nov. 17, 2023	Mar. 30, 2024	Mar. 30, 2024	Nov. 15, 2023	Nov. 06, 2023	Sep. 23, 2022
share repurchase plan [Line Items]
Stock Repurchased During Period, Value			$ 0	$ 150,000,000
Accelerated share repurchase agreement						$ 500,000,000
Accelerated Share Repurchases, Settlement (Payment) or Receipt		$ 500,000,000			$ 500,000,000
Percentage of share repurchase program		80%
Repurchase of common stock (in shares)	1,400,000	5,600,000
September 22, 2022
share repurchase plan [Line Items]
Stock Repurchase Program, Authorized Amount							$ 1,000,000,000
Stock Repurchased During Period, Shares			0	2,200,000
Stock Repurchase Program, Remaining Authorized Repurchase Amount			$ 348,600,000	$ 348,600,000
December 11, 2020
share repurchase plan [Line Items]
Stock Repurchase Program, Authorized Amount			$ 1,000,000,000	$ 1,000,000,000